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ABSTRACT 
 Tetraploid cells, which typically arise from errors in mitosis, are genomically 
unstable and promote tumorigenesis.  Recent evidence suggests that ~40% of tumors 
undergo a tetraploid intermediate during their evolution, with ~20% of all solid tumors 
maintaining a tetraploid karyotype.  Consequently, tumor suppression mechanisms have 
evolved to limit the proliferation of tetraploid cells.  However, it remains unclear how 
tetraploid cells are able to overcome these tumor suppression mechanisms to initiate 
tumorigenesis.  To address this unresolved question, we developed and validated a 
genome-wide screening assay to comprehensively identify miRNAs whose 
overexpression promotes tetraploid cell proliferation.  We then profiled those miRNAs to 
mechanistically define how each miRNA functions to overcome tetraploid induced arrest.  
Our results demonstrate that miRNAs can promote proliferation via multiple 
mechanisms, including inhibition of the p53 tumor suppressor pathway, hyperactivation 
of growth factor signaling, and inactivation of the Hippo tumor suppressor pathway.  
Additionally, we investigated mechanisms that facilitate tumorigenesis from proliferating 
tetraploid cells.  It is well established that tetraploid cell proliferation promotes both 
numerical and structural chromosome abnormalities, although the precise mechanisms 
underlying these phenomena remain incompletely understood.  Chromosome 
		 vii 
missegregation can lead to the formation of micronuclei separate from the primary 
nucleus, a result of either lagging or polar chromosomes.  Micronuclei have been shown 
to rupture during interphase, leading to massive amounts of DNA damage and 
chromothripsis, resulting in extensive DNA breaks and rearrangements.  We followed 
micronuclei formed from both lagging and polar chromosomes to determine whether all 
micronuclei are equally prone to nuclear envelope rupture.  Our results show that polar 
micronuclei have nuclear envelopes that are significantly more stable than the nuclear 
envelopes of micronuclei formed from lagging chromosomes.  Furthermore, micronuclei 
have been shown to be deficient at nuclear import of proteins.  Kinetochore assembly, 
vital for proper chromosome segregation, is dependent upon the nuclear import of many 
proteins.  We sought to establish whether micronuclei have defects in kinetochore 
assembly since without functional kinetochores, chromosomes cannot bind to the mitotic 
spindle.  We found that chromosomes in micronuclei fail to assemble kinetochores 
efficiently, and thus promote additional chromosome missegregation.  Overall, this 
dissertation identifies multiple mechanisms that facilitate tumorigenesis from tetraploid 
intermediates. 
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1   INTRODUCTION 
1.1 Clinical Significance 
Despite the multitude of research devoted to cancer biology, cancer remains the 
second leading cause of death in the United States, accounting for more than 580,000 
deaths in 2013 (Centers for Disease Control and Prevention, 2016).  As such, it is 
extremely important to continue elucidating mechanisms that cause cells to become 
tumorigenic.  Additionally, it is vital to find ways in which normal cells differ from 
cancer cells with the hope that these differences can be exploited to target and kill cancer 
cells preferentially while not affecting normal cells.  Current cancer treatments tend to 
target cells that divide rapidly, as most tumor cells proliferate much more quickly than 
normal cells.  However, this strategy has many toxic side effects on other rapidly dividing 
cells, such as cells of the blood, stomach, and intestine (DeVita & Chu, 2008).  
In an attempt to limit toxic side effects from the death of non-cancer cells, many 
targeted therapies have been developed.  Targeted therapies generally work by inhibiting 
growth factor receptors or kinases that are hyperactivated in cancer and drive tumor cell 
proliferation.  Some of the earliest targets of these therapies include the HER2 receptor in 
breast cancer, the EGF receptor in colon and non-small cell lung cancers and the receptor 
tyrosine kinase Bcr-ABL chronic myeloid leukemia (Druker et al., 2001; Huang, Shen, 
Ding, & Geng, 2014; Hudziak et al., 1989).  While targeted therapies were thought to be 
extremely promising avenues of research, the reality is that clinical response to these 
therapies is typically fleeting, with drug resistance and tumor progression occurring 
within a year (Huang et al., 2014; O'Hare, Zabriskie, Eiring, & Deininger, 2012; Pao & 
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Chmielecki, 2010).  For this reason, finding additional ways that cancer cells differ from 
normal cells, and defining how these differences can be exploited to selectively kill 
cancer cells, is of extreme importance. 
1.2 The Cell Cycle and Mitosis in Normal Cells 
 The cell cycle has four distinct phases, separated by a few important checkpoints. 
The cell cycle begins with the Gap 1 (G1) phase, during which the cell grows, 
synthesizing mRNAs and proteins in preparation for the following stages of the cell 
cycle.  In order to pass from G1 to the second phase of the cell cycle (S phase), the G1 
restriction checkpoint must be passed.  
The G1 restriction checkpoint is regulated by a number of transcription factors, 
cyclins, and cyclin-dependent kinases (CDKs).  Early in G1, retinoblastoma (Rb) binds to 
E2F transcription factors in order to inhibit the transcription of genes important for cell 
cycle progression.  As the cell progresses through G1, cyclin D accumulates, and 
complexes with CDK4 and CDK6.  Cyclin D-CDK complexes phosphorylate E2F 
transcription factors, which release Rb and begin the transcription of genes important for 
G1/S transition, such as cyclin E.  When cyclin E complexes with CDK2, the cell signals 
for transition from G1 to the next phase of the cell cycle.  If a cell contains any defects 
requiring arrest in G1, such as DNA damage, p16 and p53 accumulate.  Accumulation of 
p16 disrupts the cyclin D-CDK complexes, allowing Rb to rebind to dephosphorylated 
E2F transcription factors, arresting the cell in G1.  Accumulation of p53 leads to the 
activation of p21, an inhibitor of the cyclin E-CDK2 complex, which will also keep the 
cell from progressing to S phase.  Therefore, to pass the G1 restriction checkpoint, the 
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cell to be of a sufficient size and be free of any abnormalities, such as DNA damage.   
When the G1 restriction checkpoint is satisfied, the cell commits to proliferating 
and enters the synthesis (S) phase.  During S phase, the entire genome of the cell is 
copied.  In addition to replication of DNA, replication of the centrosome – the organelle 
responsible for serving as a microtubule organizing center during mitosis – is also strictly 
regulated during S phase.  Following S phase, the cell enters the Gap 2 (G2) phase, 
another stage responsible for growth and protein synthesis in order to prepare the cell to 
finish the cell cycle.  Once the cell passes the G2/DNA damage checkpoint, it can enter 
the final stage of the cell cycle, mitosis (M phase) (Malumbres & Barbacid, 2001).   
Mitosis is the fastest stage of the cell cycle, but it is arguably the most critical to 
proper cell proliferation.  Mitosis consists of five stages: prophase, prometaphase, 
metaphase, anaphase, and telophase, as visualized in Figure 1.1.  During prophase, the 
chromatin – chromosomes and associated proteins – condenses, making chromosomes 
visible under a microscope.  Additionally, the mitotic spindle forms, with one centrosome 
at each spindle pole, and the nuclear envelope breaks down.  During prometaphase, 
microtubules connected to the mitotic spindle poles begin binding to and capturing 
chromosomes via proteinaceous structures called kinetochores, which are built upon the 
centromeric DNA region of the chromosome.  Each chromosome has one centromere, 
located at the center of the chromosome, and will therefore also have one kinetochore.  
Chromosome alignment begins in prometaphase and completes during metaphase, at 
which point all of the chromosomes are organized at the middle of the cell.  At this stage, 
each chromosome is connected by kinetochore microtubules to a spindle pole, with one 
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copy of each paired chromosome going to each pole.  Once all of the chromosomes are 
aligned, the final cell cycle checkpoint can be satisfied.   
The final checkpoint is called the spindle assembly checkpoint (SAC); the SAC 
monitors kinetochore-microtubule attachments, and is only satisfied when each 
chromosome is properly attached to the mitotic spindle, with one sister chromatid 
attached to one spindle pole, and the second sister chromatid attached to the second 
spindle pole.  A failure of the spindle assembly checkpoint can lead to missegregated 
chromosomes, as is frequently seen in cancer (Musacchio & Salmon, 2007).  Following 
SAC satisfaction, the cell will enter anaphase, during which the paired chromosomes 
separate to opposite sides of the cell due to the loss of cohesion.  In telophase, new 
membranes form around the daughter nuclei, the chromosomes decondense, and spindle 
fibers disperse.  At the end of telophase, the cytokinetic furrow separates the two 
daughter cells from one another, and mitosis is complete. 
1.3 Aneuploidy and Chromosome Instability in Cancer 
Normal cells in the human body have 23 pairs of chromosomes – 46 
chromosomes total – and are defined as diploid.  Aneuploidy is defined as a divergence 
from any multiple of the normal diploid number of chromosomes and is a hallmark of 
many tumors.  Paradoxically, aneuploidy correlates to a decrease in fitness in cells of all 
organisms; however, it is also nearly ubiquitous in cancer cells, which are known for their 
increased proliferative potential (Holland & Cleveland, 2009; Santaguida & Amon, 
2015). 
Although aneuploidy itself does not cause chromosome instability (CIN) – a 
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persistently elevated rate of chromosome missegregation – most tumors that are 
aneuploid do missegregate chromosomes at high rates and thus are not only aneuploid, 
but also CIN (Lengauer, Kinzler, & Vogelstein, 1997).  CIN is often the result of 
geometrically abnormal spindle intermediates, caused by extra centrosomes, or defective 
microtubule dynamics (Bakhoum, Genovese, & Compton, 2009; Bakhoum, Thompson, 
Manning, & Compton, 2009; Neil J Ganem, Godinho, & Pellman, 2009; Silkworth, 
Nardi, Scholl, & Cimini, 2009).  Additionally, it has been shown that a higher degree of 
aneuploidy – defined as a number of chromosomes farther away from the normal 46 – 
leads to a higher level of CIN (Nicholson & Cimini, 2013).  Aneuploidy and chromosome 
instability is extremely problematic; CIN promotes tumor progression, relapse, and 
correlates with poor prognosis (Sotillo, Schvartzman, Socci, & Benezra, 2010; Walther, 
Houlston, & Tomlinson, 2008). 
1.4 Mechanisms of Chromosome Missegregation 
Chromosome instability as a result of chromosome missegregation is extremely 
common in cancer.  Many mechanisms can give rise to chromosome missegregation in 
cancer, including merotelic attachments, abnormalities in kinetochore-microtubule 
dynamics, loss of cohesion, and spindle assembly checkpoint defects. 
Missegregation of chromosomes, and thus chromosome instability, is most often 
the result of merotelic chromosome attachments.  The different types of chromosome 
attachments to the spindle pole can be seen in Figure 1.2A. Under normal circumstances, 
one kinetochore attaches to microtubules emanating from a single spindle pole, and its 
sister kinetochore is attached to the opposite spindle pole.  This is called an amphitelic 
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attachment, which leads to proper chromosome segregation when the cell progresses to 
anaphase.  If a pair of sister chromatid kinetochores both attach to microtubules 
emanating from the same spindle pole, this is known as a syntelic attachment. In this 
case, the spindle assembly checkpoint is activated and anaphase does not proceed until 
the syntelic attachment is corrected to an amphitelic attachment.  A single kinetochore 
that is attached to microtubules emanating from both spindle poles is known as a 
merotelic attachment, which is particularly problematic because a merotelic attachment 
satisfies the spindle assembly checkpoint (Cimini, 2008; Cimini et al., 2001; N. J. Ganem 
& Pellman, 2012; Gregan, Polakova, Zhang, Tolic-Norrelykke, & Cimini, 2011; Salmon, 
Cimini, Cameron, & DeLuca, 2005). When a cell enters anaphase with a chromosome 
that is merotelically attached, that chromosome gets pulled in both directions initially, 
and while it often does segregate into the correct daughter cell, it frequently lags behind 
the other chromosomes so severely that it forms a micronucleus separate from the rest of 
the chromosomes when the nuclear envelope forms, as seen in Figure 1.2B–C (N. J. 
Ganem & Pellman, 2012). 
Mal-attachment of microtubules at kinetochores and abnormal kinetochore-
microtubule dynamics promotes merotely and leads to CIN (Bakhoum, Genovese, et al., 
2009; Bakhoum, Thompson, et al., 2009; Ertych et al., 2014).  In normal cells, when 
microtubules incorrectly attach to a kinetochore, that mal-attachment is corrected before 
the cell enters anaphase so that the chromosomes can segregate correctly.  However, 
when incorrect kinetochore-microtubule attachments form in cancer cells that are CIN, 
these mal-attachments persist because they are inherently more stable than the 
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kinetochore-microtubule attachments formed in normal diploid cells (Bakhoum, 
Thompson, et al., 2009).  Merotelic attachments can also result from defects in mitotic 
spindle assembly, such as is seen in cells containing extra centrosomes.  Cells with extra 
centrosomes tend to undergo a multipolar spindle intermediate with three or four separate 
poles.  When a cell is in a multipolar spindle intermediate, merotelic attachments are 
more likely to form, as kinetochore-microtubule attachments stabilize before the 
centrosomes cluster to proceed through a bipolar anaphase, as depicted in Figure 1.3 
(Neil J Ganem et al., 2009; Silkworth et al., 2009). 
Another mechanism that leads to chromosome missegregation is premature 
separation of chromosome pairs due to defects in sister chromatid cohesion.  Loss of 
cohesion allows for syntelic attachments to persist while sister chromatids that experience 
cohesion that endures through anaphase are not able to properly separate from one 
another.  Both of these defects lead to a pair of sister chromatids incorrectly segregated to 
the same daughter cell.  It is not surprising then, that mutations in genes implicated in 
sister chromatid cohesion, such as the cohesion complex subunit STAG2, have also been 
identified in chromosomally unstable cancer cells (Barber et al., 2008; Solomon et al., 
2011). 
Finally, spindle assembly checkpoint defects can cause missegregation of 
chromosomes and CIN.  If the spindle assembly checkpoint malfunctions, a cell may 
proceed from metaphase to anaphase before all of the chromosomes are properly aligned 
and connected to the appropriate spindle pole.  Ergo, defects in the spindle assembly 
checkpoint will lead to chromosome missegregation.  Interestingly, mutations in spindle 
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assembly checkpoint genes have been shown to be sufficient to promote tumorigenesis 
(Musacchio & Salmon, 2007). 
There are two other types of chromosome aberrations that, while they do not 
normally lead to CIN, are also important and are the result of a failure in mitosis; they are 
chromosome fragments and chromosome bridges.  Chromosome fragments occur when a 
chromosome gets broken and the broken chromosomal fragment does not have a 
kinetochore, thus preventing it from attaching to the spindle and segregating normally 
during anaphase.  An example of a chromosome fragment is illustrated in Figure 1.4 (A).  
Chromosome bridges are the result of two chromosomes fusing together.  When two 
chromosomes, or chromosome fragments both containing centromeres, fuse together, a 
dicentric chromosome is created with two kinetochores.  If these two kinetochores 
connect to the same spindle pole during mitosis, the chromosomes will separate 
efficiently to the same daughter cell.  However, if the kinetochores connect to different 
spindle poles, then the chromosomal DNA is pulled toward both daughter cells and a 
chromosome bridge forms (N. J. Ganem & Pellman, 2012).  This bridge, which can be 
seen in Figure 1.4 (B), may be broken during cytokinesis in order for the cell to complete 
mitosis and split into two daughter cells, or may lead to cytokinesis failure and 
tetraploidy.  Occasionally, the broken chromosome from the bridge is so far behind the 
other chromosomes that a micronucleus is formed. 
1.5 Micronuclei, DNA Damage, and Chromothripsis  
When a cell undergoes a normal mitosis, two daughter cells are formed, each with 
a single nucleus, as in Figure 1.1.  However, when a cell proceeds through mitosis 
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abnormally, sometimes a micronucleus forms in addition to the primary nucleus.  A 
micronucleus is formed when a cell enters telophase with either one or a few 
chromosomes separated from the main chromosome mass such that two nuclear 
envelopes form – one around the main chromosome mass, forming the primary nucleus 
and the second around the separated chromosome(s) forming what is called a 
micronucleus, as in Figure 1.2C.  Chromosomes can become separated from the main 
nucleus and form micronuclei in multiple ways.  They can be the result of lagging 
chromosomes, chromosome bridges, or chromosome fragments, as detailed in the 
previous section.  However, micronuclei can also be the result of chromosomes that fail 
to congress to the metaphase plate; these micronuclei will be discussed more in Chapter 
3. 
No matter how they are formed, all chromosomes harbored within micronuclei are 
highly susceptible to accumulation of DNA damage.  Historically, mutations are believed 
to accumulate gradually over the course of many progressions through the cell cycle 
(Helleday, Eshtad, & Nik-Zainal, 2014; Yates & Campbell, 2012).  However, recent 
evidence has shown that a phenomenon known as chromothripsis is responsible for the 
generation of massive amounts of DNA damage all at once (Kloosterman et al., 2012; 
Rausch et al., 2012; Stephens et al., 2011; C. Z. Zhang, Leibowitz, & Pellman, 2013; C. 
Z. Zhang et al., 2015). 
Chromothripsis is a phenomenon characterized by a number of distinct features.  
The first identifying characteristic is a large number of chromosome breaks and 
rearrangements occurring on only one or a few chromosomes (Rode, Maass, Willmund, 
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Lichter, & Ernst, 2015; C. Z. Zhang et al., 2013).  These breaks originate from a single 
parental chromosome and are not properly repaired, leading to translocations formed 
from misrepaired DNA, likely from nonhomologous end-joining (Rausch et al., 2012; C. 
Z. Zhang et al., 2013). A schematic of chromosome rearrangements resulting from 
chromothripsis, including the loss of segments of DNA and the creation of ,double 
minutes – small circular fragments of DNA, is in Figure 1.5.  Finally, cells that have 
undergone chromothripsis have copy-number profiles that oscillate between only two 
states (Rausch et al., 2012; Stephens et al., 2011).   
While chromothripsis is not confined to cancer cells (it is also seen in some 
patients with congenital developmental disorders), it does occur in a wide variety of both 
primary tumors and cancer cell lines including melanoma, prostate cancer, colorectal 
cancer, small-cell lung cancer, brain tumors and blood cancers (C. Z. Zhang et al., 2013).  
Zack et al. (2013) assessed 4934 cancers and found that chromothripsis occurs at a 
frequency of ~5% overall and up to ~35% in certain cancer subtypes.  While it is still not 
known whether chromothripsis is responsible for causing tumorigenesis, evidence of 
chromothripsis has been shown to be associated with poor clinical prognosis 
(Kloosterman, Koster, & Molenaar, 2014).  It’s likely that many cells that undergo 
chromothripsis subsequently go through apoptosis due to the loss of essential genes; 
however, the cells that survive despite massive chromosome damage typically have an 
advantageous alteration.  For example, in medullablastoma, the noncoding gene PVT1 
was found to be fused with the oncogene MYC (Northcott et al., 2012; Rode et al., 2015).  
Additionally, the loss of tumor suppressor genes such as CDKN2A has been seen in 
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diffuse large B-cell lymphoma (Morin et al., 2013). Finally, oncogenes can be amplified 
on circular fragments of DNA, known as double minutes, as has been found in small cell 
lung cancer, neuroblastoma, medulloblastoma and esophageal adenocarcinoma, which 
have amplification of the oncogene MYC (Molenaar et al., 2012; Nones et al., 2014; 
Northcott et al., 2012; Stephens et al., 2011). 
A longstanding mystery in the field was how chromothripsis is confined to only 
one or two chromosomes; it has become clear over the last few years that it is a result of 
these chromosomes being sequestered in micronuclei.  DNA damage is seen in 
micronuclei that have entered S phase, but not in those that are still in G1 (Crasta et al., 
2012; C. Z. Zhang et al., 2015). This indicates that DNA damage does not simply occur 
in micronuclei, cells must also be progressing through the cell cycle and have entered S 
phase, the stage in which DNA damage accumulates.  Micronuclei have defects in 
nuclear import, which leads to inefficient DNA replication – about one third of 
micronuclei show evidence of replicating their DNA while in G2.  Furthermore, 
micronuclei have defects in DNA repair, and stalled replication forks, which is also a 
result of a lack of replication factors that are normally imported from the cytoplasm 
(Crasta et al., 2012; E. M. Hatch, Fischer, Deerinck, & Hetzer, 2013; Terradas, Martin, 
Hernandez, Tusell, & Genesca, 2012). Terzoudi et al. (2015) demonstrated that 
chromosome shattering or chromothripsis is a result of premature chromosome 
condensation following mechanical stress such as exposure to radiation.  In cells with 
micronuclei, premature chromosome condensation led to chromothripsis in micronuclei 
when the primary nuclei entered mitosis without any other outside stressors (Terzoudi et 
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al., 2015).   
Nuclear envelope rupture in micronuclei has major effects on genetic instability.  
In addition to the accumulation of massive amounts of DNA damage, DNA replication is 
severely impaired in intact micronuclei and completely abolished in ruptured micronuclei 
(Crasta et al., 2012; E. M. Hatch et al., 2013; Terradas et al., 2012).  Furthermore, DNA 
damage repair is less efficient in both intact and ruptured micronuclei (Crasta et al., 2012; 
E. M. Hatch et al., 2013).  Proliferation of cells with micronuclei can also lead to 
chromosome instability because the chromosomes within micronuclei do not properly 
replicate, leading to an abnormal chromosome number.  Furthermore, micronuclei do not 
properly assemble kinetochores and thus cannot properly align to the mitotic spindle.  
Both genetic instability and chromosome instability can lead to cancer, making 
proliferation of cells with micronuclei especially dangerous. 
Nuclear envelope rupture occurs randomly during the cell cycle, including during 
G1 (E. M. Hatch et al., 2013).  Nuclear envelope rupture is a consequence of the 
disruption of lamins, proteins that are responsible for maintaining the structure of the 
nuclear envelope as well as regulating transcription – which results in lamina gaps, and 
abnormal mechanical properties (Dahl et al., 2006; Vargas, Hatch, Anderson, & Hetzer, 
2012).   Rupture results in a loss of the barrier between nuclear and cytoplasmic cellular 
components.  Consequently, rupture leads to the exposure of DNA to cytoplasmic 
components such as DNAses and mRNA processing machinery (Vargas et al., 2012). 
Since DNA damage is not seen in micronuclei in G1, even though nuclear 
envelope rupture does often occur in G1, rupture does not cause damage by itself. It was 
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recently shown that chromothripsis is in fact the result of the massive amount of DNA 
damage resulting from micronuclei rupture after entry into S phase; the importance of the 
timing of nuclear envelope rupture is likely due to the sudden compaction of DNA that is 
still replicating when the cell enters mitosis (C. Z. Zhang et al., 2013; C. Z. Zhang et al., 
2015).  It could also be the result of the loss of replication factors or the exposure of 
DNA in the nucleus to DNAses that are normally confined to the cytoplasm (Vargas et 
al., 2012). Anaphase bridges may have the same propensity for fragmentation as do 
micronuclei, though this has not yet been shown (Rode et al., 2015). 
It is known that cancer cells are more prone to nuclear envelope rupture of the 
primary nucleus than are normal cells (Vargas et al., 2012).  The mechanism behind this 
rupture is poorly understood; however, the nuclear envelope is nearly always repaired 
when rupture occurs in the primary nucleus (Cohen, Marr, Garcin, & Pante, 2011; de 
Noronha et al., 2001; De Vos et al., 2011; Vargas et al., 2012).  This is in contrast to the 
nuclear envelopes of micronuclei, which generally remain fragmented, failing to regain 
compartmentalization, even when the cell enters mitosis (E. Hatch & Hetzer, 2014).  
Micronuclei rupture, as with primary nuclear rupture, is generally due to disruption of 
lamins, which results in lamina gaps (E. M. Hatch et al., 2013).  It is unclear why 
micronuclei have a high probability of rupturing while primary nuclei do not.  One 
hypothesis as to why micronuclei are prone to rupture is that micronuclei have a 
significantly higher curvature than primary nuclei, which could cause an extra stress level 
on the disrupted lamina.  However, Hatch et al. (2013) found that micronuclei that are 
significantly larger rupture at the same rate as smaller micronuclei; this suggests that the 
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rupture is likely due to a lack of lamins or lamin discontinuity as a result of defects in 
formation of the nuclear lamina.  
1.6 The p53 Pathway Limits Tumorigenesis 
The p53 tumor suppressor pathway plays a key role in limiting the growth of 
genetically abnormal cells.  When a non-transformed cell acquires DNA damage or 
experiences other forms of cellular stress, such as a failure in mitosis leading to 
tetraploidy, the p53 pathway is activated. This leads either to cell cycle arrest until the 
DNA damage can be corrected or apoptosis if the damage proves to be irreparable 
(Schmitt et al., 2002).  When active, p53 – a transcription factor – binds to DNA and 
activates the expression of several genes responsible for DNA repair.  Activated p53 also 
induces cell cycle arrest by inducing expression of p21, a cyclin-dependent kinase 
inhibitor, which inhibits the activity of multiple cyclin-dependent kinases that promote 
G1/S transition.  Accumulation of p21 prevents cells from replicating their DNA, thus 
ensuring that DNA damage is fixed before the cell progresses in the cell cycle.  
Suppression of the p53 pathway promotes tumorigenesis and permits genetic instability 
that often results in aneuploidy.  More than half of human tumors harbor a mutation or 
deletion in the gene encoding for p53 (Hollstein, Sidransky, Vogelstein, & Harris, 1991; 
Schmitt et al., 2002).  
Activation of p53 is antagonized by MDM2, an E3 ubiquitin ligase.  When cells 
are not experiencing stress or abnormalities such as DNA damage, MDM2 ubiquitinates 
p53, tagging it for degradation.  Additionally, p53 is responsible for transcribing MDM2, 
leading to a negative feedback loop which keeps p53 levels low in healthy cells (Barak, 
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Juven, Haffner, & Oren, 1993; Chen, Marechal, & Levine, 1993; Picksley & Lane, 1993; 
Wu, Bayle, Olson, & Levine, 1993).  Interruption of the interaction of MDM2 and p53 is 
what leads to p53 activation in cells that are experiencing stress.  The MDM2-p53 
interaction can be disrupted in various ways – such as phosphorylation or acetylation of 
p53 – depending on the particular stressor, but the end result is p53 stabilization leading 
to cell cycle arrest until either the damage can be repaired or it undergoes senescence or 
apoptosis (Moll & Petrenko, 2003). 
1.7 Tetraploidy and Cancer 
In contrast to normal cells, tetraploid cells have four copies of each chromosome, 
twice the normal DNA content.  Tetraploidy can result from numerous mechanisms, as 
shown in Figure 1.6.  The first method leading to tetraploidy is endoreduplication, the 
replication of the nuclear genome in the absence of cell division.  Tetraploidy can also be 
the result of cell fusion, which is usually the result of viral infections, but can also happen 
spontaneously (Storchova & Pellman, 2004).  Most often, however, tetraploidy is the 
result of a failure in mitosis or cytokinesis, processes that involve hundreds of proteins 
(T. Davoli & de Lange, 2011; N. J. Ganem, Storchova, & Pellman, 2007).   
Under normal circumstances, tetraploid cells arrest in G1, the first stage of the 
cell cycle, and undergo either senescence or apoptosis due to the p53-dependent tumor 
suppression mechanism, which will be discussed in more detail in a subsequent section.  
However, in certain abnormal circumstances – such as when the p53 tumor suppression 
mechanism is impaired – tetraploid cells can proliferate; these cells are genetically 
unstable and can promote tumorigenesis (T. Davoli & de Lange, 2011; Teresa Davoli & 
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de Lange, 2012; Duelli et al., 2007; Fujiwara et al., 2005; N. J. Ganem et al., 2007).  
Tetraploidy is particularly significant as it has been shown that ~20% of all solid tumors 
are near-tetraploid, defined as cells having >70 chromosomes.  Remarkably, ~40% of all 
tumors show evidence of whole genome doubling – being tetraploid at some point in the 
development of the tumor (T. Davoli & de Lange, 2011; N. J. Ganem et al., 2007).  
Certain cancer subtypes, such as osteosarcoma and liver adenocarcinoma, have 
particularly high rates of tetraploidy. 
The idea that tetraploidy can cause cancer is actually a very old one.  Over 100 
years ago, Theodor Boveri postulated that an abnormal number of chromosomes could 
lead to cancer (Boveri, 2008).  However, it was Fujiwara and colleagues (2005) who 
were the first to show, in an elegant experiment, that tetraploid cells cause cancer if the 
p53 tumor suppressor pathway is impaired. They treated primary p53-null mammary 
epithelial cells with a drug to prevent cytokinesis and make otherwise normal cells 
tetraploid; these tetraploid cells and their normal diploid counterparts were then 
transplanted back into mice.  The result showed that while the transplanted diploid cells 
did not form any tumors, the tetraploid cells formed near-tetraploid tumors in the mice 
(Fujiwara et al., 2005).   
The proliferation of tetraploid cells promotes tumorigenesis in a number of ways; 
the most important factor is probably the development of chromosome instability.  
Chromosome instability occurs when chromosomes persistently accumulate both 
numerical and structural aberrations as a consequence of errors in mitosis; this ongoing 
instability has been shown to promote tumor progression, relapse, and poor prognosis 
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(Lengauer et al., 1997; Sotillo et al., 2010; Walther et al., 2008).  
Tetraploid cell proliferation also promotes tumorigenesis through genomic 
instability, including chromosome breaks and rearrangements – in which portions of 
some chromosomes are translocated and attach to other chromosomes (Fujiwara et al., 
2005; N. J. Ganem et al., 2007).  Genome instability is often a result of impaired DNA 
mismatch repair, resulting in deletions or substitutions of a few nucleotides (Lengauer, 
Kinzler, & Vogelstein, 1998).  Larger amounts of DNA damage can lead to 
chromothripsis and genetic instability in micronuclei (C. Z. Zhang et al., 2015). 
Finally, tetraploid cells can promote tumorigenesis through buffering effects 
(Dewhurst et al., 2014; N. J. Ganem et al., 2007; Thompson, Desai, & Murray, 2006).  
Possessing four copies of each chromosome may help overcome any deleterious 
mutations in tetraploid cells if said mutations are at least partially recessive.  The longer a 
tetraploid cell survives with deleterious mutations that would normally kill a diploid cell, 
the more likely it is that a crucial oncogenic mutation will arise, promoting tumorigenesis 
(N. J. Ganem et al., 2007). 
1.8 Proliferating Tetraploid Cells are Chromosomally Unstable 
The proliferation of tetraploid cells is problematic largely because it leads to 
chromosomal instability due to the presence of extra centrosomes.  For this reason, the 
centrosome duplication cycle is precisely regulated (Nigg, Cajanek, & Arquint, 2014).  
The centrosome, which serves as a microtubule organizing center during mitosis, is 
composed of two centrioles and a mass of pericentriolar material.  Centriole duplication 
begins as the cell transitions from G1 to S phase, and the centrioles separate as pictured 
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in Figure 1.7.  Centriole duplication is complete by the end of G2, and each new pair of 
centrioles forms a centrosome. The centrosomes separate at the beginning of mitosis, 
forming two separate spindle poles from which microtubules emanate to facilitate proper 
chromosome attachments and segregation.   
Normal cells have one centrosome that is duplicated throughout the cell cycle; 
when the cell enters anaphase, the spindle poles are pushed apart from one another 
leading each daughter cell to again have one centrosome when cytokinesis is complete.  
Tetraploid cells, however, have at least one extra centrosome; this is due to the 
mechanisms leading to tetraploidy (refer to Figure 1.6).  For example, if tetraploidy is a 
result of mitotic slippage or failure of cytokinesis, the centrosome has already duplicated 
so the tetraploid cell now has two centrosomes in G1.  Thus, when tetraploid cells go 
through mitosis, they frequently have four centrosomes and four spindle poles 
corresponding to those centrosomes.  This occasionally leads to multi-polar cell 
divisions, where one cell divides into more than two daughter cells.  These multi-polar 
divisions would lead to a large amount of aneuploidy; however multi-polar divisions 
typically give rise to inviable cells for this very reason – while a small amount of 
aneuploidy is tumorigenic, large amounts of aneuploidy leads to cell death (Neil J Ganem 
et al., 2009; Silk et al., 2013; Weaver, Silk, Montagna, Verdier-Pinard, & Cleveland, 
2007).  
More frequently, tetraploid cells pass through a transient multipolar spindle 
intermediate, but then cluster their extra centrosomes into two poles, enabling a more 
normal bipolar cell division, as seen in Figure 1.3.  However, the abnormal geometry of 
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the multipolar intermediate predisposes chromosomes to inappropriately attach to the 
mitotic spindle, and this leads to a dramatic increase in missegregation of chromosomes 
and formation of micronuclei due to merotelic attachments (Neil J Ganem et al., 2009).  
1.9 Tetraploidy Indirectly Promotes DNA Damage  
and Chromosomal Structural Aberrations 
Tetraploid cells, in addition to having an abnormal number of chromosomes, 
often contain dramatic amounts of DNA damage and chromosomal structural aberrations, 
such as breaks and translocations of large portions of DNA (Crasta et al., 2012; N. J. 
Ganem & Pellman, 2012; Vargas et al., 2012).  These dramatic abnormalities, though not 
a direct result of tetraploidy, are in fact an indirect result of tetraploid cell proliferation.  
Tetraploid cells containing extra centrosomes pass through a multipolar spindle 
intermediate, promoting chromosome mal-attachments.  Some of these mal-attachments 
will result in micronuclei formation due to the severity of lagging behind the main 
chromosome mass.  Consequently, these micronuclei will undergo chromothripsis as the 
cell progresses through S phase, leading to chromosomes with massive amounts of DNA 
damage and translocations being partitioned into tetraploid daughter cells (Crasta et al., 
2012; E. M. Hatch et al., 2013; E. M. Hatch & Hetzer, 2015; C. Z. Zhang et al., 2013; C. 
Z. Zhang et al., 2015).  As tetraploid cells proliferate, and various chromosomes are 
confined to micronuclei, DNA damage and structural aberrations will continue to 
accumulate leading to cells with potentially increased tumorigenic potential. 
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1.10 Tumor Suppression Mechanisms Limit the Proliferation of Tetraploid Cells 
The existence of a mechanism to limit the proliferation of tetraploid cells was first 
discovered in 1967 when Carter observed that cells treated with cytochalasins led to the 
accumulation of binucleate tetraploid cells due to cytokinesis failure (Carter, 1967).  
Further studies confirmed that cytokinesis failure in nontransformed cell lines led to the 
accumulation of binucleate tetraploid cells (Wright & Hayflick, 1972). However, 
transformed cells treated with the same drugs as the nontransformed cells did not 
accumulate as binucleate tetraploid cells.  Instead, they proliferated as normal cells 
would, forming a population of multinucleate tetraploid cells (Wright & Hayflick, 1972).   
Additionally, tetraploid cells generated by mitotic slippage arrest in G1, just as 
tetraploid cells generated from cytokinesis failure (Andreassen, Lohez, Lacroix, & 
Margolis, 2001; Rieder & Maiato, 2004).  Arrest in G1 was shown to involve the p53 
tumor suppressor pathway; cells that have a defect in p53 are capable of overcoming G1 
arrest and re-entering the cell cycle (Andreassen et al., 2001; Cross et al., 1995; Khan & 
Wahl, 1998; Lanni & Jacks, 1998; Minn, Boise, & Thompson, 1996).  This indicates that 
some mechanism exists to limit the proliferation of tetraploid cells, irrespective of how 
tetraploidy arises.  This mechanism is termed the “tetraploidy checkpoint” which is 
dependent on the p53 tumor suppressor pathway.  
The existence of the tetraploidy checkpoint is actually somewhat controversial.  
There are multiple reasons for this; first, normal hepatocytes are often tetraploid and 
these cells are able to proliferate without issue (Guidotti et al., 2003).  Second, although 
tetraploidy is rare in humans, polyploid plants and amphibians are often seen in nature 
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(Storchova & Pellman, 2004).  Moreover, although nontransformed cells arrest 
universally when induced to be tetraploid, the methods used to create tetraploid cells may 
have induced G1 arrest because those methods were themselves particularly stressful. For 
example, tetraploid cells that failed cytokinesis because they were treated with 10 µM 
cytochalasin arrested in G1 while those generated with treatment of only 0.5 µM 
cytochalasin generally divide normally (Uetake & Sluder, 2004). 
One theory to reconcile the controversy of the existence of the tetraploidy 
checkpoint is that G1 arrest of tetraploid cells is the result of a combination of stressors.  
Tetraploidy itself is one stressor, which combined with cytoskeletal defects, or DNA 
damage leads to p53-dependent cell cycle arrest in G1.  
1.11 The Hippo Pathway Limits the Proliferation of Tetraploid Cells 
The controversy of the tetraploidy checkpoint has recently been reconciled.  It 
was shown that the Hippo pathway causes G1 arrest, and that it takes time for the Hippo 
pathway to be fully engaged, so not all tetraploid cells arrest immediately (N. J. Ganem et 
al., 2014).  
Canonically, the Hippo pathway is responsible for regulating organ size and 
keeping cells from overgrowing their environment (Pan, 2010; Yu & Guan, 2013).  The 
Hippo pathway was discovered in drosophila when it was observed that deletion of the 
gene Warts (analogous to LATS2 in humans) led many organs to grow much larger than 
their normal size (Justice, Zilian, Woods, Noll, & Bryant, 1995; T. Xu, Wang, Zhang, 
Stewart, & Yu, 1995).  Subsequently, a number of other genes were identified as 
similarly increasing tissue size in drosophila; these genes were shown to interact with one 
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another and collectively they make up the Hippo pathway (Yu, Zhao, & Guan, 2015). 
Hippo pathway signaling occurs via a kinase cascade that becomes activated 
when cells are contact inhibited, cells detach, or organs reach their full size as is depicted 
in Figure 1.8.  The critical portion of the Hippo pathway is the regulation of large tumor 
suppressor kinase 2 (LATS2) on the transcriptional coactivators yes-associated protein 
(YAP) and transcriptional co-activator with PDZ binding domain (TAZ).  LATS2 is a 
kinase that is active when phosphorylated; LATS2 inactivates YAP/TAZ by 
phosphorylation, keeping YAP and TAZ in the cytoplasm where they either associate 
with the 14-3-3 complex, or are degraded by the proteasome.  When LATS2 is inactive, 
YAP/TAZ become active and enter the nucleus where they interact with the transcription 
factor TEAD and are responsible for the transcription of many genes responsible for cell 
proliferation (Yu & Guan, 2013). 
The Hippo pathway can be activated either by diffusible signals or by mechanical 
cues.  Rho is a GTPase that regulates cell contractility and tension by stimulating actin 
polymerization; Rho activity inhibits LATS2, inactivating the Hippo pathway through G-
protein coupled receptor signaling (Dupont et al., 2011; Halder, Dupont, & Piccolo, 
2012; Yu & Guan, 2013; Yu et al., 2012; B. Zhao et al., 2012; B. Zhao et al., 2007).  
Additionally, when cells contact one another, mechanical signals are received and the 
Hippo pathway is activated via Merlin (NF2 in humans). Merlin is a cytoskeletal linker 
protein that mediates phosphorylation of MST1 and MST2, which in turn phosphorylates 
LATS1 and LATS2, facilitated by the scaffolding proteins Sav1 and Mob.  LATS2 
phosphorylation leads to YAP/TAZ inactivation by phosphorylation and/or degradation.  
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Thus, when the Hippo pathway is activated, cell growth is restricted, and Hippo pathway 
inactivation leads to cell proliferation (Yu & Guan, 2013).   
The Hippo pathway also has tumor suppressor function through its interaction 
with the p53 pathway.  LATS2, when active, binds to and inactivates the E3 ubiquitin 
ligase MDM2 (Aylon et al., 2006).  MDM2 targets p53 for destruction; therefore, an 
active Hippo pathway not only halts cell proliferation by inactivating YAP and TAZ, it 
also acts by inhibiting MDM2, thus stabilizing p53. 
It has recently been shown that a novel mechanism responsible for G1 arrest in 
tetraploid cells is activation of the Hippo tumor suppressor pathway (N. J. Ganem et al., 
2014).  Ganem and colleagues (2014) generated binucleate tetraploid cells by preventing 
cytokinesis with dihydrocytochalasin B.  They then assessed what genes enabled 
tetraploid cell proliferation by performing a genome-wide siRNA screen.  The strongest 
hit from the screen specific to tetraploid arrest was a key component of the Hippo 
pathway, LATS2.  Ganem et al. (2014) found that tetraploid cells had significantly more 
phosphorylated LATS2 than normal diploid cells and that the kinase activity of LATS2 
was necessary for G1 arrest of tetraploid cells, indicating Hippo pathway activation in 
cell cycle arrested tetraploid cells.  YAP was correspondingly phosphorylated and 
localized to the cytoplasm in tetraploid cells as compared to diploid cells that had nuclear 
localized YAP.  Furthermore, tetraploid cells with constitutively active YAP or YAP 
overexpression overcame G1 arrest; this data is shown in Figure 1.9. 
Tetraploid cells were shown to activate the Hippo pathway as a result of 
containing extra centrosomes, providing the mechanistic basis for the reduced 
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proliferation of tetraploid cells (N. J. Ganem et al., 2014).  Extra centrosomes activate 
Rac1 through centrosomal microtubule assembly (Godinho et al., 2014).  Active Rac1 
antagonizes RhoA, a member of the Rho family of GTPases that is responsible for 
cytoskeleton regulation, though actin fiber formation and actomyosin contractility 
necessary for cytokinesis; RhoA is significantly decreased in tetraploid cells relative to 
normal diploid cells.  Reactivation of RhoA enabled tetraploid cell proliferation by 
inactivating the Hippo pathway and decreasing the amount of p53. 
1.12 Additional Mechanisms that Bypass Tetraploid-Induced Cell Cycle Arrest 
In addition to inactivation of the Hippo pathway, the screen by Ganem et al. 
(2014) found that depletion of negative regulators of growth factor signaling also 
overcame the arrest of tetraploid cells; thus increased growth factor signaling is capable 
of overcoming tetraploid-induced cell cycle arrest.  There are many receptor tyrosine 
kinases (RTKs) that are responsible for signaling that a cell should proliferate.  Activated 
RTKs initiate many downstream signaling cascades, two of the most important, in Figure 
1.10, are the MAPK pathway and the PI3K pathway.  These pathways are extremely 
important as they regulate cell survival, growth, and proliferation, and both have been 
shown to be mutated or dysregulated in a vast number of cancers. 
The MAPK pathway consists of the Ras-Raf-Mek-ERK signaling cascade.  Ras is 
a GTPase, anchored to the plasma membrane within the cell.  When the pathway in 
inactive, Ras is bound to GDP; however in response to external signals such as growth 
factors or cytokines, Ras is activated by an exchange of GDP to GTP.  The activation is 
mediated by Grb2 (growth factor receptor bound protein 2), an adaptor protein, and SOS 
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(son of sevenless), a guanine nucleotide exchange factor.  Replacement of GDP with 
GTP causes a conformational change in Ras, recruiting Raf to the plasma membrane, and 
activating its kinase activity.  Raf, a kinase, activates MEK, another kinase, that activates 
ERK, the downstream effector of the MAPK pathway.  ERK acts by phosphorylating 
numerous genes important for survival, proliferation, and differentiation (Santarpia, 
Lippman, & El-Naggar, 2012).  Dysregulation of the MAPK pathway is extremely 
common in cancers – point mutations in RAF and RAS family genes are found in ~30% 
of all cancers.  Furthermore, Ras has been shown to be activated by EGFR; EGFR 
overexpression can be a result of ERK activation, a dangerous positive feedback loop for 
tumor growth that is also seen in many cancers (Santarpia et al., 2012). 
The PI3K pathway is also important for regulating cell growth and proliferation.  
PI3K enzymes are activated by RTKs as well as G-protein-coupled receptors.  When 
activated, the class I PI3Ks produce PIP3, a phospholipid that anchors to the plasma 
membrane.  PIP3 facilitates activation of AKT by phosphorylation; AKT, when activated, 
is responsible for phosphorylating many substrates, such as mTOR, leading to growth, 
survival, and metabolism through both pro-growth genes and inhibition of pro-apoptotic 
proteins including MDM2 (Carracedo & Pandolfi, 2008).  A major regulator of the PI3K 
pathway is PTEN, a lipid phosphatase that de-phosphorylates PIP3 on the plasma 
membrane, thereby inhibiting the PI3K pathway.  Modifications of the PI3K pathway are 
also common in cancer; PI3K enzymes have been shown to be amplified or mutated in a 
range of cancers including breast, colorectal, and ovarian cancer.  Additionally, PTEN is 
commonly mutated or lost in human cancer, causing PI3K to be more active as it cannot 
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be inhibited efficiently by PTEN (Carracedo & Pandolfi, 2008). 
Since growth factor signaling is upregulated in cancer, many chemotherapeutics 
have been developed that target either the MAPK or PI3K pathway.  These treatments, 
however, have largely been unsuccessful at curing patients.  This is likely due, at least in 
part, to cross-talk between the MAPK and PI3K pathways.  This cross-talk can be either 
inhibitory or excitatory.  For example, MEK inhibitors induce activation of AKT, the 
downstream target of the PI3K pathway; AKT itself negatively regulates the MAPK 
pathway by phosphorylating Raf at inhibitory sites, indicative of pathway cross-
inhibition.  Conversely, the MAPK pathway can also activate the PI3K pathway through 
active Ras, which can bind to PI3K, activating the pathway (Mendoza, Er, & Blenis, 
2011).  
Clearly, growth factor signaling is extremely important in cancer in general.  
Moreover, hyperactivation of growth factor signaling was one mechanism that enables 
proliferation of tetraploid cells (N. J. Ganem et al., 2014).  Previous studies have also 
shown that genetic conditions that subtly activate growth factor signaling are sufficient to 
induce tetraploid cell proliferation (Bellacosa, Kumar, Di Cristofano, & Testa, 2005; Yap 
et al., 2008). 
1.13 The Hippo Pathway and Cancer 
The Hippo pathway has recently been shown to be an important tumor suppressor 
pathway, particularly in tetraploid cells (N. J. Ganem et al., 2014; Harvey, Zhang, & 
Thomas, 2013; L. Lu et al., 2010; Song et al., 2010; Zhou et al., 2009).  The Hippo 
pathway functions to suppress proliferation of cells once they become contact inhibited; 
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when cells inactivate the Hippo pathway, they continue to proliferate, thus promoting 
tumorigenesis.  In mice, Hippo pathway inactivation has been shown to promote the 
overgrowth of normal tissue as well as the development of tumors (Camargo et al., 2007; 
Dong et al., 2007; L. Lu et al., 2010; Song et al., 2010; Zhou et al., 2009).  Hippo 
pathway inactivation is seen in numerous cancers, including colon, lung, ovarian, and 
liver (Harvey et al., 2013; Steinhardt et al., 2008).  Furthermore, Hippo pathway 
inactivation has been associated with cancer metastasis and is indicative of poor 
prognosis in ovarian and hepatocellular carcinomas (Hall et al., 2010; Harvey et al., 
2013; M. Z. Xu et al., 2009; X. Zhang et al., 2011; B. Zhao et al., 2012). 
Although Hippo pathway inactivation is common in many cancers, mutations in 
Hippo pathway components are quite rare.  Indeed, Merlin is the only gene that has been 
observed to be mutated in Hippo inactivated cancers (Harvey et al., 2013).  Nevertheless, 
Hippo pathway inactivation is common, often through amplification or overexpression of 
YAP (Overholtzer et al., 2006; Zender et al., 2006).  Conversely, Hippo pathway 
inactivation can be the result of epigenetic silencing of upstream regulators MST1, 
MST2, LATS1, or LATS2 (Harvey et al., 2013; Jiang et al., 2006; Seidel et al., 2007; 
Takahashi et al., 2005).  Reactivation of the Hippo tumor suppressor pathway could be a 
potentially important therapeutic for cancer patients. 
1.14 miRNAs and Cancer 
MiRNAs have been gaining attention as being key regulators of gene expression, 
and have been shown to play key roles in tumor progression (Garzon, Calin, & Croce, 
2009).  MiRNAs are small, non-coding RNAs; they are ~21–25 nucleotides long and 
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regulate gene expression either by preventing translation or silencing mRNA. As can be 
seen in Figure 1.11, each miRNA is transcribed in the nucleus as a primary-miRNA (pri-
miRNA) and processed by Drosha to form a precursor-miRNA (pre-miRNA), a hairpin 
structure about 70 nucleotides long that is exported from the nucleus to the cytoplasm.  
Once in the cytoplasm, the pre-miRNA is processed by Dicer into the active miRNA 
which is ~21–25 nucleotides long.  The active miRNA can act in one of two ways.  The 
more common method is known as translational repression; in this scenario, the miRNA 
forms a complex with RNA-induced silencing complex (RISC) and targets the open 
reading frame (ORF), preventing the ribosome from translating mRNA.  In the second 
mechanism, mRNA cleavage, the miRNA forms a complex with RISC and directly 
targets mRNA, silencing it by cleavage.  Each miRNA is responsible for regulating 
hundreds to thousands of individual genes (L. He & Hannon, 2004). 
In general, miRNAs are globally downregulated in tumor cells compared to 
normal cells. Consistent with this observation, the partial loss of Dicer has been shown to 
promote tumorigenesis, with 27% of tumors exhibiting hemizygous deletion of Dicer 
(Kumar et al., 2009; Lambertz et al., 2010).  Despite global downregulation, there is a 
subset of miRNAs that are upregulated in cancers, particularly in solid tumors (Volinia et 
al., 2006). Additionally, it has been postulated that quantification of serum miRNAs 
could be useful for early diagnosis of hematologic malignancies and solid tumors (Boeri 
et al., 2011). 
Several miRNAs have already been identified as being significantly up- or down-
regulated in certain cancers (Garzon et al., 2009).  Since each miRNA has hundreds to 
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thousands of target mRNA sequences, determining the role of each miRNA is extremely 
difficult; indeed, some miRNAs are up-regulated in some specific cancer subtypes while 
down-regulated in others.  For example, miR-221 is tumor suppressive in erythroblastic 
leukemia while promoting tumorigenesis in solid tumors such as colon, pancreatic and 
stomach cancers (Felli et al., 2005; Garofalo, Quintavalle, Romano, Croce, & Condorelli, 
2012; Volinia et al., 2006). 
Some miRNAs have been identified as having known functions; for example the 
373 family has been shown to have a tumor-suppressive role by targeting the NF-kB and 
TGF-B pathways in estrogen receptor negative breast cancer (Keklikoglou et al., 2012).  
However, most miRNAs have unknown roles, especially in regards to the pathways that 
overcome tetraploid-induced arrest.  With better understanding, miRNAs represent a 
potential therapeutic – miRNAs that are oncogenic could be targeted with inhibitors such 
as antagomiRs or antimiRs while miRNAs that are tumor suppressive could be given as a 
therapy in the form of miRNA mimetics (Bader, Brown, & Winkler, 2010; Di Leva, 
Garofalo, & Croce, 2014; Krutzfeldt et al., 2007). Dysregulation of miRNAs also leads to 
chemoresistance in many cancer patients, indicating that a combination therapy which 
includes miRNA mimetics or antagomiRs may be of relevance in chemotherapy patients 
(Magee, Shi, & Garofalo, 2015). 
1.15 Interactions between miRNAs and the Hippo Pathway 
There have been a limited number of studies showing that individual miRNAs 
either activate or inactivate the Hippo tumor suppressor pathway.  The paper to first show 
inactivation of the Hippo pathway by a miRNA identified miR-373 as a post-
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transcriptional regulator of LATS2, a key regulator of the Hippo pathway, though they 
did not look at YAP or TAZ localization (Lee et al., 2009). More recent papers have 
additionally categorized miR-31, miR-125a, miR-130b, and miR-135b (Lin et al., 2013; 
Mitamura et al., 2014; Nandy et al., 2015; Zhu et al., 2015).  Targets for these miRNAs 
have not been identified, and none of these papers performed a whole genome screen of 
all the known miRNAs.  On the other hand, miRNAs that activate the Hippo pathway 
have been relatively well characterized.  MiR-125, miR-141, and miR-338 activate the 
hippo pathway by targeting TAZ directly; miR-132 and miR-506 target YAP directly; 
and miR-129 directly targets both YAP and TAZ (Higashi et al., 2015; Hua et al., 2015; 
Lei et al., 2015; Li, Fang, Yu, & Wang, 2015; A. M. Liu, Poon, & Luk, 2010; P. Liu et 
al., 2015; Tan et al., 2015; Y. Wang et al., 2014; Yuan et al., 2015; Z. W. Zhang et al., 
2013; Zuo et al., 2015).  Furthermore, miR-338 and miR-106b activate the Hippo 
pathway indirectly, by targeting CUL4A and ITCH, respectively (Deng et al., 2016; Luo 
et al., 2016). 
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Figure 1.1:  The stages of mitosis.   
Mitosis begins with chromatin condensation and nuclear envelope breakdown in prophase and prometaphase, continues with 
chromosome alignment at the spindle midzone in metaphase and chromosome separation to opposite spindle poles in 
anaphase.  Mitosis concludes with nuclear envelope reformation and chromosome decondensation in telophase, which is 
immediately followed by cytokinesis, which results in the creation of two daughter cells.  
Image obtained from https://publications.nigms.nih.gov/insidethecell/ch4_phases_allbig.html 	
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Figure 1.2: Types of chromosome-microtubule attachments 
(A) The types of microtubule attachments that can occur when a cell is in metaphase.  (B) A cell going through anaphase with 
a lagging chromosome caused by a merotelic attachment: chromosomes, green; kinetochores, red. (C) Micronuclei formed as a 
result of the merotelic attachment/lagging chromosome in (B). 
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Figure 1.3: Mitosis in cells with extra centrosomes 
Cells with extra centrosomes progress through mitosis by (A) first forming a multi-polar 
spindle intermediate then (B) clustering centrosomes into a bipolar spindle before 
entering anaphase. (C–D) Due to the multi-polar spindle intermediate, merotelic 
attachments are more likely to persist, resulting in lagging chromosomes and the 
formation of micronuclei. Adapted from (Neil J Ganem et al., 2009). 	
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Figure 1.4: Additional types of chromosome aberrations 
(A) Chromosome fragment in anaphase. (B) Chromosome bridge in anaphase that is a 
result of chromosome fusion. Chromosomes: green; Kinetochores: red 
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Figure 1.5:  Mechanism of chromothripsis in one or two chromosomes 
Chromothripsis leads to complex chromosome rearrangements, as well as potential loss 
of chromosome segments and creation of double minutes.  (A) Damage resulting from a 
micronucleus containing one chromosome. (B) Damage resulting from a micronucleus 
containing two chromosomes; when multiple chromosomes undergo chromothripsis, 
exchange of chromosome fragments can occur. (Forment, Kaidi, & Jackson, 2012) 
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Figure 1.6: Mechanisms leading to tetraploidy 
Tetraploid cells can be the result of (A) cell fusion, (B) endoreduplication or (C) mitotic 
slippage or cytokinesis failure.  Adapted from Storchova and Pellman (2004). 
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Figure 1.7: Centrosome duplication cycle 
The centrosome duplication cycle is tightly regulated during S phase so that there are 
exactly two centrosomes during mitosis (Mustaly, 2015). 
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Figure 1.8: The Hippo tumor suppressor pathway.   
When the Hippo tumor suppressor pathway is active, LATS1/2 phosphorylates YAP and 
cells do not proliferate.  When inactive, YAP enters the nucleus and co-activates the 
transcription of proliferative and anti-apoptotic genes.   
Image obtained from http://www.pancreapedia.org/pathways/hippo-signaling 
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Figure 1.9: LATS2 inhibits tetraploid cell proliferation by stabilizing p53 and inactivating YAP.   
(A) Western blot of p53, LATS2, and YAP levels in diploid (2N) and tetraploid (4N) cells transfected with the indicated 
siRNAs. (B) Representative images of 2N and 4N RPE-FUCCI cells overexpressing either empty vector control (control), 
YAP wild-type (YAP-WT), or constitutively active YAP (YAP-S5A), with quantitation of the percentage of S/G2 cells for 
each condition shown on the right. (C) Western blot analysis of p53 and LATS2 levels in 2N, 4N, and doxorubicin-treated 2N 
(2N+Dox) RPE-FUCCI cells transfected with the indicated siRNAs. (D) Coimmunoprecipitation of HA-tagged LATS2-WT 
and endogenous MDM2 from 2N and 4N RPE-1 cells using anti-HA antibodies. (N. J. Ganem et al., 2014) 
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Figure 1.10: MAPK and PI3K growth factor signaling pathways  
The MAPK pathway signals through the kinase Ras, which phosphorylates the kinase 
Raf, which phosphorylates the kinase Mek, which phosphorylates the downstream 
regulator ERK. The PI3K pathways signals through the downstream regulators AKT and 
mTOR.  Both of these pathway are commonly mutated or upregulated in cancer.  
(Nikiforov & Nikiforova, 2011) 
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Figure 1.11: Depiction of miRNA synthesis and mechanisms of action.   
A primary miRNA (pri-miRNA) is transcribed from DNA, processed into a precursor 
miRNA (pre-miRNA) by Drosha, exported from the nucleus by exportin 5, and processed 
to an active miRNA by Dicer.  The miRNA acts on its target mRNA either through 
translation repression or mRNA cleavage (L. He & Hannon, 2004). 
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2   MIRNAS THAT ENABLE TETRAPLOID CELL PROLIFERATION 
2.1 Introduction 
Tetraploid cells, cells that have twice the DNA content of normal cells, have been 
postulated to cause cancer for over one hundred years, with conclusive evidence coming 
when Fujiwara and colleagues injected mice with tetraploid cells, leading to the 
formation of tumors in those mice (Boveri, 2008; Fujiwara et al., 2005).  Investigating 
tetraploidy is critical because ~20% of all solid tumors are near-tetraploid with ~40% of 
all tumors showing evidence of whole genome doubling, meaning that the tumor was 
tetraploid at some point in its evolution (T. Davoli & de Lange, 2011; N. J. Ganem et al., 
2007).   
When cells become tetraploid – either by endoreduplication, cell fusion, mitotic 
failure, or cytokinetic failure, as shown in Figure 1.6 – they arrest in G1 due to activation 
of the Hippo tumor suppressor pathway and, correspondingly, the p53 tumor suppressor 
pathway (N. J. Ganem et al., 2014).  Arrest of tetraploid cells in G1 is an extremely 
important tumor suppression mechanism as proliferating tetraploid cells lead to cancer.  
In order to understand the genes and pathways important for G1 arrest of tetraploid cells, 
Ganem and colleagues (2014) performed a genome-wide siRNA screen and identified 
three main mechanisms that enable tetraploid cells to proliferate: inactivation of the p53 
tumor suppressor pathway; hyperactivation of growth factor signaling; and inactivation of 
the Hippo tumor suppressor pathway. 
While it is now known what genes enable tetraploid cell proliferation, it is not 
known how miRNAs affect tetraploid cell proliferation.  MiRNAs are important 
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regulators of gene expression, with each miRNA able to target hundreds to thousands of 
individual genes.  While miRNA expression is generally downregulated in cancer, a 
number of miRNAs have been found to be overexpressed in various cancers, though it 
was not reported which of these tumors may have been tetraploid (Kumar et al., 2009; 
Lambertz et al., 2010; Volinia et al., 2006).  We were therefore interested in identifying 
which miRNAs are important for tetraploid cell proliferation. 
We hypothesized that overexpression of some miRNAs would be important for 
enabling tetraploid cell proliferation.  We therefore investigated which miRNAs enable 
tetraploid cell proliferation when overexpressed by performing a genome-wide screen of 
all the known human miRNAs.  After identifying the miRNAs that enabled proliferation 
of tetraploid cells, we identified the general mechanism each miRNA uses to cause cells 
to overcome tetraploid-induced arrest: inhibition of the p53 tumor suppressor pathway; 
hyperactivation of growth factor signaling; or inactivation of the Hippo tumor suppressor 
pathway.   
2.2 Methods 
2.2.1 Cell Culture 
Retinal pigment epithelial (RPE) cells and RPE cells expressing the fluorescence 
ubiquitination cell cycle indicator (FUCCI) system were grown and maintained at 40–
80% confluency in DMEM:F12 media supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin.  HEK293A cells were grown and maintained at 40–80% 
confluency in Hyclone DMEM-High Glucose media supplemented with 10% FBS and 
	44 
1% penicillin/streptomycin. All cells were kept in an incubator at 37°C supplemented 
with 5% CO2. 
2.2.2 Protein Collection and Western Blotting 
All protein collections were performed as follows.  Cells were washed twice in 
cold PBS and lysed using RIPA buffer containing protease and phosphatase inhibitors.  
Lysates were incubated while rocking for 10 min on ice and centrifuged at 14,000 x g at 
4°C to remove the cell membranes.  The protein supernatant was added to Laemmli’s 
buffer and boiled for 5 min at 95°C.   
Protein extracts were run on 7.5% or 12% Biorad polyacrylamide gels at 130V, 
transferred onto PVDF membranes using the Biorad wet transfer system at 350mA for 90 
min, and blocked in 5% milk in TBS-0.5% Tween for 1 hr.  PVDF membranes were 
incubated overnight with primary antibody; bound antibody was detected using 
horseradish peroxidase-linked secondary antibodies and visualized using ECL or ECL 
Prime.  All antibodies were diluted in 1% milk in TBS-0.5% Tween. 
2.2.3 Immunofluorescence 
Cells on coverslips were fixed and stained as follows.  Each coverslip was washed 
with PBS for 1 minute and fixed using 4% paraformaldehyde in PBS for 15 minutes.  
Cells were then extracted for 5 minutes in PBS-0.5% Triton and blocked in TBS-5% 
BSA for 30 minutes.  Cells were incubated in primary antibody for 1 hr, washed in PBS 
for 1 min then TBS-5% BSA for 5 min, incubated in fluorescently-labeled secondary 
antibody for 30 min, washed in PBS for 1 min then TBS-5% BSA for 5 min.  Primary 
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antibodies were diluted in TBS-5% BSA while secondary antibodies were diluted in 
TBS-5% BSA + Hoechst to stain the DNA.  Finally, coverslips were mounted to slides 
using Prolong Antifade Gold.  Coverslips were imaged using a Nikon Eclipse Ti 
microscope with Nikon perfect focus and an Andor camera at 20x. 
2.2.4 Identification of miRNAs that Enable Tetraploid Cell Proliferation 
We performed a screen of all the known human miRNAs using the same 
screening assay used in the siRNA screen performed by Ganem et al. (2014) as seen in 
Figure 2.1.  Tetraploid cells were generated and purified as detailed in Appendix A.  
Briefly, normal RPE-1 FUCCI cells were treated with dihydrocytochalasin B (DCB) – a 
drug that prevents cytokinesis by inhibiting actin polymerization – for 16 hr in order to 
create tetraploid RPE-1 FUCCI cells.  In the FUCCI system, cells that are in G1 express 
mCherry labeled hCdt1, a protein only expressed in G1; these cells fluoresce red.  Cells 
that are in S, G2, or M phase of the cell cycle express Azami Green labeled geminin, a 
protein that is only expressed in S/G2/M phases; these cells fluoresce green.   In order to 
isolate tetraploids, cells were first sorted using fluorescence-activated cell sorting (FACS) 
by staining the DNA with Hoechst and isolating those cells that have four copies of each 
chromosome (4C) from those that have only two copies of each chromosome (2C).  
However, cells with 4C can either be tetraploid cells arrested in G1 or diploid cells that 
have gone through S phase, and therefore duplicated their chromosomes.  The FUCCI 
system allows us to sort these cells from one another as the G1 arrested tetraploid cells 
are red while the S/G2/M phase diploid cells are green.  After isolation by FACS, the 
tetraploid cells were plated into 384-well plates for screening.  Cells were reverse-
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transfected with the Ambion miRNA library, ~1000 miRNAs targeting the human 
genome; p53 siRNA was used as a positive control to enable tetraploid cell proliferation.  
Fluorescent images were obtained 96 h after miRNA treatment to determine the fraction 
of proliferating tetraploid cells.  MiRNAs that promote tetraploid cell proliferation were 
identified by the presence of green fluorescing cells.  A miRNA was considered to 
promote tetraploid cell proliferation if it led to a percentage of cells fluorescing green that 
has a Z-score greater than or equal to 3, indicating that the percent of proliferating cells is 
at least three standard deviations higher than that of the negative control. 
2.2.5 Assessing p53 Pathway Activation 
In order to assess whether the p53 tumor suppressor pathway is inhibited, we 
assessed protein expression using western blots.  While p53 is the upstream regulator of 
this tumor suppressor pathway, p21 is also an important regulator downstream of p53.  In 
order to assess p53 pathway activation, RPE-1 cells were plated in 6-well plates at a 
concentration of 70,000 cells/well.  The following day, cells were transfected with either 
precursor negative control or target miRNAs obtained from Ambion for 48 hours.  For 
the last four hours, cells were treated with doxorubicin to induce DNA damage, 
activating the p53 pathway.  Protein was collected using RIPA buffer as described 
previously and probed for p53 and p21, and actin as an internal control. 
2.2.6 Assessing Growth Factor Signaling 
To analyze activation of growth factor signaling, RPE-1 cells were plated in 6-
well plates at a concentration of 70,000 cells/well.  The following day, cells were 
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transfected with precursor negative control or target miRNAs.  After 48 hours of 
transfection, the cells were serum starved for 24 hours.  Protein was collected under 
serum starved conditions and 1 hr after the addition of media containing 5% serum.  
Levels of AKT and p-AKT were used as a readout of growth factor signaling and 
assessed using western blot.  Those miRNAs that activate growth factor signaling were 
defined as having a larger p-AKT:AKT ratio than the cells transfected with precursor 
negative control miRNA.  We followed up on the growth factor signaling of miR-191 by 
performing a time-course of serum stimulation.  In this experiment, RPE-1 cells were 
plated, transfected, and serum starved in the same way as for the larger screen.  However, 
cells were stimulated for 5 hr and protein was collected 0, 10, 30, 60, and 300 min 
following stimulation with media containing 5% serum.  Protein was collected and 
visualized using the protocol detailed in section 2.2.2. 
2.2.7 Assessing Hippo Pathway Inactivation 
Hippo pathway activation was determined using immunofluorescence to visualize 
YAP localization.  Coverslips were washed with 70% ethanol, placed in 12-well plates, 
and rinsed twice with complete media.  RPE-1 cells were plated on coverslips in 12-well 
plates at a concentration of 35,000 cells/well.  The next day, cells were transfected with 
precursor negative control or target miRNAs for 48 hr.  Cells were fixed and stained for 
YAP using the protocol detailed in section 2.2.3.  YAP fluorescence was quantified as the 
fluorescence intensity in the nucleus compared to the fluorescence intensity in the 
cytoplasm.  Any miRNAs that had significantly more nuclear YAP than the negative 
control was characterized as having inactivated the Hippo pathway. 
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As YAP is a transcriptional coactivator that binds to TEAD, we validated 
activation of the Hippo pathway using qPCR to analyze transcript levels of YAP target 
genes.  RPE-1 cells were plated in 6-well plates, 70,000 cells/well.  The next day, cells 
were transfected with negative control precursor miRNA, miR-24, or LATS 1/2 siRNA 
as a positive control.  RNA was extracted and cDNA made to perform qPCR.  Hippo 
pathway activation was evaluated by evaluating expression of the YAP target genes 
CTGF, CYR61, FSTL1, and MFAP5, using actin as an internal control. 
2.2.8 Preparation of cDNA and qPCR 
We used RT-qPCR to measure RNA transcript levels.  RNA was extracted using 
the Qiagen RNEasy kit, following all instructions: collecting a single well of a 6-well 
plate in 350 µl RLT buffer and homogenizing each sample by passing it 5 times through 
a 20 gauge needle.  The extracted RNA was made into cDNA using 500 ng of RNA and 
the Thermo Fisher Superscript III First-Strand Synthesis kit. Random hexamers were 
used to make the cDNA, which was diluted 1:15 in nuclease free water to be used for RT-
qPCR. 
Plates were prepared for RT-qPCR using SYBR green.  Each well of a 96-well 
plate contained 12.5 µl SYBR green mix, 1.5 µl forward primer (5 µM stock), 1.5 µl 
reverse primer (5 µM stock), 4.5 µl nuclease free water, and 5 µl cDNA.  Each plate was 
run using an Applied Biosystems qPCR machine and StepOne software, cycling between 
95°C and 55°C for 40 cycles for all genes except for MFAP5 which ran for 50 cycles as it 
was late amplifying. 
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2.3 Results 
2.3.1 Genome-Wide Screen Identifies miRNAs that Enable Tetraploid Cell Proliferation 
We performed a screen on all of the known human miRNAs to identify those 
miRNAs that enable tetraploid cells to overcome their cell cycle arrest.  Tetraploid cells 
arrested in G1 were generated and purified as described previously then seeded into 384-
well plates for screening.  Each well was reverse-transfected with a different precursor 
miRNA and automated image analysis was used 96 hours post-transfection to determine 
the percentage of cells with green fluorescence, indicative of cell proliferation. 
The primary screen, in which each miRNA was screened in triplicate, produced 
87 hits – defined as having a Z-score > 3; the Z-score indicates how many standard 
deviations away from the negative control each miRNA falls.  These 87 miRNAs were 
screened a second time, and 43 miRNAs again had a Z-score > 3.  These hits can be 
found in Table 2-1.  It is important to note that the miRNAs that did not replicate were 
generally right at the limit of having a Z-score of 3. Representative images of the data 
obtained from this screen can be found in Figure 2.2.  
Three general pathways have been identified as being involved in enabling 
tetraploid cell proliferation: inhibition of the p53 pathway; upregulation of growth factor 
signaling; and inhibition of the Hippo pathway (Ganem et al., 2014).  As such, we 
performed further screens on each miRNA that enabled tetraploid cell proliferation to 
determine through which of these pathways each miRNA acts. 
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2.3.2 Some miRNAs Inhibit the p53 Tumor Suppressor  
Pathway to Enable Tetraploid Cell Proliferation 
The most obvious way that cells could be overcoming tetraploid-induced arrest is 
by turning off the p53 tumor suppressor pathway as it is one of the most important factors 
in preventing undesirable cell proliferation.  While p53 is the upstream regulator of this 
tumor suppressor pathway, p21 is also an important regulator downstream of p53.  Also 
known as cyclin-dependent kinase inhibitor 1, p21 inhibits the activity of multiple cyclin-
dependent kinases and therefore functions as a cell cycle regulator.  If either p53 or p21 
are inhibited in the presence of DNA damage or tetraploidy, cells will progress through 
the cell cycle when they should be arrested in G1.  We therefore expected that some of 
the miRNAs identified by our screen were overcoming tetraploid-induced arrest by 
turning off the p53 tumor suppressor pathway.  In order to test this hypothesis, we treated 
normal RPE-1 cells with doxorubicin (Dox) to induce DNA damage, and consequently 
p53 pathway activation.  We also transfected Dox treated RPE-1 cells with each miRNA 
to determine which miRNAs target the p53 pathway.  We transfected Dox treated RPE-1 
cells with p53 siRNA or p21 siRNA as positive controls for inhibition of the p53 tumor 
suppressor pathway.  The results, seen in Figure 2.3, identified p53 as a target of miR-
520c and miR-520g, while p21 is a target of miR-298, miR-373, miR-520h, and miR-
523.  Untreated negative control cells do not activate p53 or p21 while the positive 
control, cells treated with Dox, but transfected with negative control miRNA, clearly 
activates p53 and p21.  We did not evaluate whether these miRNAs target p53 and p21 
directly, or if they have an indirect effect on protein levels by targeting a regulator of 
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p53/p21 expression.    
2.3.3 miRNAs Upregulate Growth Factor Signaling  
to Enable Tetraploid Cell Proliferation 
It has been established that another way to overcome tetraploid-induced arrest is 
to hyperactivate growth factor signaling.  Therefore, we looked at growth factor 
stimulation as measured by the ratio of p-AKT to AKT in serum starved RPE-1 cells.  
RPE-1 cells were transfected with either precursor negative control or targeted miRNAs 
for 48 hr and then serum starved for 24 hr.  Cells were collected following serum 
starvation in order to assess relative protein levels.  The data in Figure 2.4 show that miR-
106a, miR-191, miR-298, miR-302a, miR-302b, miR-302c, miR-302d, miR-373, miR-
520b, miR-520d, miR-520e, miR-520g, and miR-523 all upregulate growth factor 
signaling with respect to the negative control precursor miRNA. 
Noting that miR-191 was one of the most significant hits for upregulation of 
growth factor signaling, and was one of the strongest hits of the screen, we performed a 
longer time course investigating the effects of serum stimulation on cells transfected with 
miR-191.  We also singled out miR-191 as it has been identified as being oncogenic in 
many types of cancer, including liver, breast, colon, lung, pancreas, prostate, and stomach 
cancers (Di Leva et al., 2013; Elyakim et al., 2010; Y. He et al., 2011; Qin et al., 2014; 
Taguchi & Murakami, 2013; Volinia et al., 2006).  RPE-1 cells were still transfected for 
48 hr before 24 hr serum starvation; however, protein was collected 0, 10, 30, 60, and 
300 min after stimulation with media containing 5% serum.  These data, shown and 
quantified in Figure 2.5, show an upregulation and sustained growth factor signaling as 
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measured by an increased p-AKT:AKT ratio for cells treated with miR-191 with respect 
to the miRNA negative control, specifically at the 60 and 300 min time points. 
2.3.4 miRNAs Inactivate the Hippo Pathway to Enable Tetraploid Cell Proliferation 
The canonical function of the Hippo pathway is to stop proliferation when cells 
are contact inhibited or organs reach their full size.  More recently, the Hippo pathway 
has also been shown to be activated in tetraploid cells (N. J. Ganem et al., 2014).  When 
the Hippo pathway is activated, LATS2 is phosphorylated; this phosphorylates YAP and 
keeps YAP out of the nucleus.  Since YAP is responsible for the transcription of a wide 
variety of genes, many of which are responsible for cell growth, cells are restricted from 
proliferation when the Hippo pathway is active.  Conversely, when the Hippo pathway is 
inactivated, YAP goes into the nucleus where it is responsible for transcription and cell 
growth.  We probed for Hippo pathway inactivation using immunofluorescence staining 
for YAP. Normal RPE-1 cells were plated on coverslips, transfected with a precursor 
miRNA, and fixed using paraformaldehyde before staining for YAP.   
Figure 2.6 shows representative images of cells transfected with each miRNA, 
with the quantification of these experiments in Figure 2.7.  These data indicate that only 
one miRNA – miR-24 – has YAP significantly localized to the nucleus, indicative of 
Hippo pathway inactivation (N = 7, p = 0.0061).  Significance was evaluated using a two 
tailed t-test.  LATS 1/2 siRNA was used as a positive control because without LATS 1/2, 
YAP cannot be phosphorylated and therefore localizes to the nucleus.  Since the only hit 
from the screen that significantly inactivates the Hippo pathway was miR-24, and 
surprisingly it did so to a larger extent than the positive control, LATS 1/2, we wanted to 
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validate this finding.  To validate inactivation of the Hippo pathway by miR-24 we 
performed RT-qPCR to evaluate the known YAP target genes CTGF, CYR61, FSTL1, 
and MFAP5.  The results of the RT-qPCR are in Figure 2.8 and show that miR-24 
upregulates the expression of YAP target genes in RPE-1 cells. 
To verify that Hippo pathway inactivation of miR-24 was not cell line specific, 
we used HEK293A cells and transfected them with negative control precursor miRNA, 
miR-24 precursor, and LATS 1/2 as the positive control.  The results from these 
experiments, with representative images in Figure 2.9 and quantification of the data in 
Figure 2.10, show that miR-24 inactivates the Hippo pathway in HEK293A levels also, 
and this result is significant using a two tailed t-test (N=3, p = 0.0033). 
MiR-24 is upregulated in many cancers and also is associated with poor prognosis 
and resistance to chemotherapeutics (Braoudaki et al., 2016; R. Liu et al., 2015; K. Lu et 
al., 2015; Volinia et al., 2006; L. Wang et al., 2015; H. Zhang et al., 2016; G. Zhao et al., 
2015; Zheng et al., 2015).  As such we aimed to identify the miR-24 target that enabled 
tetraploid cells to proliferate through inactivation of the Hippo pathway.  We tested 
known regulators of the Hippo pathway, including LATS1, LATS2, MST1, MST2, 
Merlin, MARK2 and AMOTL1.  The western blots shown in Figure 2.11 show that miR-
24 does not inhibit the Hippo pathway by decreasing the protein levels of LATS1, 
LATS2, MST1, MST2, Merlin, MARK2, or AMOTL1 in RPE-1 cells.  Surprisingly, 
MST2 and AMOTL1 appear to actually be upregulated by miR-24 in RPE-1 cells.  
Therefore, miR-24 appears to inactivate the Hippo pathway in a way independent from 
the canonical Hippo pathway components. 
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2.4 Conclusion 
We performed a screen of all the known human miRNAs and identified 26 
miRNAs that enable tetraploid cells to proliferate.  We then tested those miRNAs to 
determine whether they inhibit the p53 tumor suppressor pathway, hyperactivate growth 
factor signaling, or inactivate the Hippo tumor suppressor pathway.  We found that of the 
hits from the screen, six miRNAs inhibit either p53 or p21, thirteen miRNAs upregulate 
growth factor signaling, and one miRNA inactivates the Hippo tumor suppressor 
pathway.  We were not able to definitively characterize the mechanisms enabling 
tetraploid cell proliferation of the other miRNAs.   
The inability to identify how a particular miRNA enables tetraploid cell 
proliferation could be due to a variety of factors.  First, since miRNAs have hundreds to 
thousands of targets, it is likely that some of these miRNAs enable tetraploid cell 
proliferation by affecting more than one pathway.  If this were the case, by probing only 
one mechanism at a time, we would not necessarily be able to identify miRNAs that have 
compound effects.  Another likely possibility is that more miRNAs enable tetraploid cell 
proliferation by hyperactivating growth factor signaling, and we did not identify them 
because we only looked at AKT and p-AKT levels at one time point.  It is probable that if 
we had looked at ERK and p-ERK levels or had looked at growth factor signaling at 
multiple time points we would have identified more miRNAs that enable tetraploid cell 
proliferation through upregulation of growth factor signaling.  It’s also possible that there 
is an unknown mechanism that enables tetraploid cell proliferation; however, this seems 
like an unlikely explanation since the genome wide siRNA screen performed by Ganem 
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and colleagues (2014) identified only those three pathways as mechanisms to overcome 
tetraploid-induced arrest. 
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Figure 2.1: Genome-wide miRNA screening assay protocol 
Protocol to screen of all known human miRNAs to identify miRNAs that overcome cell cycle arrest in tetraploid cells. 
Tetraploid cells were generated by cytokinesis failure, purified using FACS, plated in 384 plates, transfected with miRNA, and 
imaged 7 days later to identify miRNAs that induced cell proliferation.  Hits from this screen were determined by measuring 
the percentage of green cells compared to the negative control, since green cells are progressing through the cell cycle. 	
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Table 2.1: Hits identified by 
the genome-wide miRNA 
screen  
MiRNA hits identified as 
enabling tetraploid cells to 
overcome G1 arrest. The Z-
score indicates how many 
standard deviations each 
miRNA hit is away from the 
negative control precursor 
miRNA.  The Average % 53 
indicates the percentage of 
cells that are green (and thus 
proliferating) when 
normalized to the positive 
control, p53 siRNA. 
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Figure 2.2: Representative images from miRNA screen 
Representative images of data obtained from the miRNA screen; the scrambled siRNA is 
the negative control, the p53 smart pool is the positive control, and hsa-miR-520g is one 
of the miRNA hits identified by the screen. 
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Figure 2.3: miRNA hits tested for inactivation of the p53 tumor suppressor pathway 
RPE-1 cells were transfected with the indicated miRNAs for 48 hr and then treated with Doxorubucin (Dox) 4 hr prior to 
protein collection.  miR-520c and miR-520g target p53 while miR-298, miR-373, miR-520h, and miR-523 target p21. 	
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Figure 2.4: miRNA hits screened for hyperactivation of growth factor signaling. 
miR-106a, miR-191, miR-298, miR-302a, miR-302b, miR-302c, miR-302d, miR-373, 
miR-520b, miR-520d, miR-520e, miR-520g, and miR-523 all hyperactivate growth factor 
signaling in serum starved conditions as compared to the negative control. 
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Figure 2.5:  Serum stimulation for cells transfected with miR-191 
A time course shows that miR-191 upregulates growth factor signaling at both the 60- 
and 300-minute time points compared to the negative control. 
 
  
	62 
 
Figure 2.6: miRNA hits tested for Hippo pathway inactivation.  
Representative images of YAP immunofluorescence for all miRNA hits, negative control, 
LATS 1/2 siRNA positive control for Hippo pathway inactivation and high density as a 
control for Hippo pathway inactivation. 
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Figure 2.7: miRNA hits tested for Hippo pathway inactivation.  
Quantification of YAP fluorescence intensity in the nucleus minus YAP fluorescence intensity in the cytoplasm, normalized to 
the negative control. 	
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Figure 2.8: mRNA expression of YAP target genes  
YAP target gene expression in negative control and miR-24 transfected RPE-1 cells.  
CTGF, CYR61, FSTL1, and MFAP5 were all upregulated in miR-24 transfected cells, 
indicating Hippo pathway inactivation. 	
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Figure 2.9: Representative images of Hippo pathway activation in HEK293A cells 
Representative images of Hippo pathway activation in HEK293A cells as measured by 
localization of YAP immunofluorescence. Cells were transfected with negative control 
precursor miRNA, LATS 1/2 siRNA or miR-24; LATS 1/2 siRNA is a positive control 
for Hippo pathway inactivation. 
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Figure 2.10: Quantification of Hippo pathway activation in HEK293A cells 
Hippo pathway activation in HEK293A cells as measured by localization of YAP 
immunofluorescence. Cells were transfected with negative control precursor miRNA, 
LATS 1/2 siRNA or miR-24; LATS 1/2 siRNA as a positive control for Hippo pathway 
inactivation.  miR-24 significantly inactivates the Hippo pathway in HEK293A cells. 
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Figure 2.11: Effects of miR-24 on Hippo pathway components 
miR-24 does not inactivate the Hippo pathway through components of the canonical 
Hippo pathway 
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3   NUCLEAR ENVELOPE STABILITY IN MICRONUCLEI 
3.1 Introduction 
3.1.1 Micronuclei, DNA Damage, and Chromothripsis 
When a cell goes through mitosis normally, two daughter cells are formed, each 
with a single nucleus.  However, defects in mitosis can give rise to chromosome 
segregation errors that leads to a chromosome that is significantly separated from the 
main chromosome mass, ultimately giving rise to a micronucleus.  Micronuclei can be 
the result of chromosomes that are incorrectly attached to the mitotic spindle and lag 
behind the main chromosome mass in anaphase, as was detailed in chapter 1.  
Micronuclei can also be the result of chromosomes that fail to congress to the metaphase 
plate, as will be discussed in more detail in section 3.1.3. 
Regardless of the mechanism of formation, chromosomes within micronuclei are 
known to be highly susceptible to the accumulation of DNA damage, leading to 
chromothripsis – a phenomenon where a massive amount of breaks and translocations 
accumulate all at once (Kloosterman et al., 2012; Stephens et al., 2011; C. Z. Zhang et al., 
2013; C. Z. Zhang et al., 2015).  DNA damage is not seen in micronuclei in G1 phase, but 
is seen in cells that have progressed to S/G2/M phase (Crasta et al., 2012).  Recently, it 
was shown that chromothripsis is dependent on nuclear envelope rupture after entry into 
S phase (C. Z. Zhang et al., 2015).  
Nuclear envelope rupture occurs randomly during the cell cycle and is typically 
the result of the disruption of lamins, which are the proteins responsible for preserving 
nuclear envelope structure (E. M. Hatch et al., 2013; Vargas et al., 2012).  Nuclear 
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envelope rupture, which occurs more frequently in micronuclei than in primary nuclei, 
triggers the loss of the barrier between the nuclear and cytoplasmic cellular 
compartments.  This leads to the exposure of DNA to cytoplasmic components such as 
DNAses which likely leads to an increased level of DNA damage and genetic instability 
(E. M. Hatch et al., 2013; Vargas et al., 2012).   
It is unclear why micronuclei have a high probability of rupturing while primary 
nuclei do not.  One hypothesis as to why micronuclei are prone to rupture is that 
micronuclei have a significantly higher curvature than primary nuclei, which could cause 
extra stress on the disrupted lamina.  However, Hatch et al. (2013) found that micronuclei 
that are significantly larger rupture at the same rate as smaller micronuclei; this suggests 
that the rupture is likely due to a lack of lamins or lamin discontinuity as a result of 
defects in nuclear lamina formation.  The formation of the nuclear lamina is regulated by 
the kinase Aurora B, which could be a key regulator of nuclear envelope rupture. 
3.1.2 Aurora B Kinase and Its Role in Nuclear Envelope Reassembly 
The nuclear envelope breaks down early in mitosis to facilitate chromosome 
segregation and is reassembled in late telophase; these processes are regulated in large 
part by the kinase Aurora B.  Along with INCENP, survivin, and borealin, Aurora B is 
part of the chromosomal passenger complex, which is necessary for a variety of functions 
during mitosis, such as globally inhibiting chromosome decondensation and nuclear 
envelope formation (Afonso et al., 2014; Meyer, Drozdowska, & Dobrynin, 2010; 
Ramadan et al., 2007).  Recent research in drosophila has shown that Aurora B can delay 
nuclear envelope reassembly as the cell progresses from anaphase into telophase (Afonso 
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et al., 2014; Karg, Warecki, & Sullivan, 2015).  This delay occurs when there are lagging 
chromosomes or chromosome bridges; in most cases, it allows the lagging chromosome 
to be reincorporated with the main nucleus (Afonso et al., 2014). When Aurora B activity 
is diminished, nuclear envelope reassembly is not delayed, signifying that Aurora B 
activity is required for a delay in nuclear envelope reassembly (Afonso et al., 2014; Karg 
et al., 2015).  If the nuclear envelope reassembles before the lagging chromosome rejoins 
the main chromosome mass, then a micronucleus will form as a nuclear envelope will 
eventually form around the isolated chromosome. 
In addition to being important for nuclear envelope assembly, Aurora B is 
responsible for a variety of functions, from assembling and stabilizing the mitotic spindle 
early in mitosis to regulating abscission, the final step of cytokinesis (Glotzer, 2009; 
Ruchaud, Carmena, & Earnshaw, 2007).  By delaying cytokinesis when there is a 
chromosome bridge, Aurora B helps to prevent tetraploidization (Mackay, Makise, & 
Ullman, 2010). 
Notably, Aurora B is essential for mediating proper attachments between 
kinetochores and microtubules so that chromosomes undergo proper segregation in 
anaphase. In order to accomplish this vital task, Aurora B destabilizes incorrect syntelic 
and merotelic attachments while stabilizing proper amphitelic kinetochore-microtubule 
attachments (Andrews et al., 2004; Cimini, Wan, Hirel, & Salmon, 2006; Hauf et al., 
2003; Lampson, Renduchitala, Khodjakov, & Kapoor, 2004; Tanaka et al., 2002). When 
improper attachments are present, Aurora B destabilizes them by phosphorylating 
NDC80, a component of the kinetochore (Cheeseman, Chappie, Wilson-Kubalek, & 
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Desai, 2006; DeLuca et al., 2006). Phosphorylation of the NDC80 complex component 
KNL1 causes release of bound microtubules, allowing the kinetochore to find proper 
microtubules to which it can attach.  When microtubules are properly attached to the 
kinetochores and the chromosome is bioriented, the tension generated pulls the 
kinetochore away from the chromosomal passenger complex, and Aurora B activity, 
thereby stabilizing the kinetochore-microtubule attachments as shown in Figure 3.1 
(Lampson & Cheeseman, 2011; D. Liu, Vader, Vromans, Lampson, & Lens, 2009).  
In metaphase, Aurora B is located at the centromeres in order to mediate proper 
kinetochore-microtubule attachments.  As the cell progresses to anaphase, Aurora B 
moves from the centromeres and localizes at the spindle midzone.  While localized at the 
spindle midzone, Aurora B generates a phosphorylation gradient with the highest levels 
of phosphorylation at the spindle midzone, and the lowest levels of phosphorylation at the 
spindle pole (Fuller et al., 2008).  As Figure 3.2 shows, Fuller et al. (2008) determined 
that the phosphorylation gradient was predominantly dependent on centromere position 
rather than time by using a chromatin-targeted Aurora B FRET sensor while tracking the 
chromosomes as the cells moved through anaphase.  They further confirmed that histone 
H3, a known target of Aurora B, displayed a higher level of phosphorylation in 
chromosomes closer to the spindle midzone than those nearer to the spindle pole (Fuller 
et al., 2008). 
3.1.3 Centrophilic Chromosomes and the Role of CENP-E 
Spindle assembly and chromosome congression defects can lead to chromosome 
missegregation that is the result of chromosomes that are localized to the spindle poles – 
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known as centrophilic, or polar, chromosomes.  A cell with polar chromosomes is shown 
in Figure 3.3.  Centromere-associated protein-E (CENP-E) is a kinesin that is important 
for proper chromosome alignment and stabilization at metaphase (Putkey et al., 2002; 
Schaar, Chan, Maddox, Salmon, & Yen, 1997; Wood, Sakowicz, Goldstein, & Cleveland, 
1997; Yao, Abrieu, Zheng, Sullivan, & Cleveland, 2000). CENP-E localizes to 
unattached kinetochores during prometaphase and mediates chromosome congression as 
shown in Figure 3.4.  CENP-E is a plus-end directed motor protein that “walks” along 
existing bundles microtubules, known as K fibers, which are attached to properly 
bioriented chromosomes at the spindle midzone. In this way, CENP-E can take a 
chromosome that is only attached to microtubules emanating from one spindle pole and 
bring it to the spindle midzone where it biorients by attaching to microtubules emanating 
from the opposite spindle pole as well (Kapoor et al., 2006).  
When CENP-E is not present, anywhere from one to many chromosomes fail to 
align at the metaphase plate, instead localizing at the spindle pole (McEwen et al., 2001; 
Schaar et al., 1997; Weaver et al., 2003; Wood et al., 1997; Yao et al., 2000).  These 
misaligned chromosomes are not attached to spindle microtubules and as a result fail to 
congress to the metaphase plate, remaining at the spindle pole in a V shape characteristic 
of chromosomes in prometaphase (Putkey et al., 2002). 
Despite a high percentage of cells with centrophilic chromosomes, CENP-E null 
MEFs do not induce a sustained mitotic arrest, leading to a high level of chromosome 
missegregation and aneuploidy (Weaver et al., 2003). This is in contrast to CENP-E 
depleted HeLa cells which do undergo mitotic arrest (Harborth, Elbashir, Bechert, 
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Tuschl, & Weber, 2001; McEwen et al., 2001; Schaar et al., 1997; Yao et al., 2000).  This 
apparent contradiction is likely a result of the number of misaligned chromosomes; most 
of the CENP-E null MEFs in Weaver’s study (2003) had only one or two misaligned 
chromosomes while CENP-E null HeLa cells had an average of over 7 misaligned 
chromosomes leading to a larger amount of checkpoint signaling. When all kinetochores 
were kept from attaching to microtubules, the MEFs did arrest in mitosis (Weaver et al., 
2003).  CENP-E null MEFs also had lower levels of BubR1, Mad1, and Mad2 
recruitment to kinetochores, all of which are proteins required for spindle assembly 
checkpoint activation (Weaver et al., 2003).  This diminished checkpoint response to a 
single misaligned chromosome could be why cells progress through mitosis which is 
extremely problematic as it leads to aneuploidy. 
Abrogation of CENP-E activity is not the only mechanism that can generate polar 
chromosomes.  Partial reduction of CENP-E through hemizygous deletion also leads to 
missegregation of chromosomes without activating a checkpoint response (Silk et al., 
2013). Furthermore, although the effect is not as dramatic as with CENP-E depletion, 
polar chromosomes are also present in cells depleted of Bub1, Bub3, and Mad2, which 
are all important spindle assembly checkpoint proteins (Babu et al., 2003; Logarinho, 
Resende, Torres, & Bousbaa, 2008; Medendorp et al., 2010; Silk et al., 2013).   
Without CENP-E, not all chromosomes properly align at the spindle midzone and 
since CENP-E depletion also abrogates response of the spindle assembly checkpoint, 
cells are more likely to progress into anaphase with misaligned chromosomes. 
Progression through anaphase with misaligned chromosomes can lead to aneuploidy, the 
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formation of micronuclei, and cancer.  In fact, decreased CENP-E expression has been 
shown in hepatocellular carcinoma, and mice that are hemizygous for CENP-E are more 
prone to developing spleen and lung tumors than wild-type controls (Z. Liu et al., 2009; 
Weaver et al., 2007).  Perhaps surprisingly, CENP-E loss can also act as a tumor 
suppressor if a tumor is already chromosomally unstable.  This indicates that tumors 
benefit from a low level of chromosome instability but cannot handle a high level of 
chromosome instability (Silk et al., 2013; Weaver et al., 2007). 
We investigated whether the position of a missegregated chromosome has an 
effect on the underlying biology of the micronuclei.  Specifically, we hypothesized that a 
polar chromosome that missegregates away from Aurora B activity would have a nuclear 
envelope that was more stable than that of a lagging chromosome that missegregates in 
an area of high Aurora B activity due to its role in delaying nuclear envelope reassembly.  
Consequently, the more stable nuclear envelope would prevent rupture and the 
accumulation of DNA damage in the micronuclear chromosomes. 
3.2 Methods 
3.2.1 Cell Culture 
Retinal pigment epithelial (RPE-1) cells and RPE-1 cells stably expressing green 
fluorescent protein-labeled histones (GFP-H2B) and red fluorescent protein labeled-
nuclear localization signal (RFP-NLS) were grown and maintained at 40–80% 
confluency in phenol red free DMEM:F12 media supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin.  The osteosarcoma cell line U2OS was also 
grown and maintained at 40–80% confluency in phenol red free DMEM:F12 media 
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supplemented with 10% FBS and 1% penicillin/streptomycin as were U2OS cells stably 
expressing GFP-H2B and RFP-NLS. All cells were kept in an incubator at 37°C 
supplemented with 5% CO2. 
3.2.2 Immunofluorescence 
Cells plated on coverslips were fixed and stained as follows.  Each coverslip was 
washed with PBS for 1 minute and fixed using 4% paraformaldehyde in PBS for 15 
minutes.  Cells were then extracted for 5 minutes in 0.5% Triton in PBS and blocked in 
TBS-5% BSA for 30 minutes.  Cells were incubated in primary antibody for 1 hr, washed 
in PBS for 1 min then TBS-5% BSA for 5 min, incubated in fluorescently-labeled 
secondary antibody for 30 min, washed in PBS for 1 min then TBS-5% BSA for 5 min.  
Primary antibodies were diluted in TBS-5% BSA while secondary antibodies were 
diluted in TBS-5% BSA + Hoechst to stain the DNA.  Finally, coverslips were mounted 
to slides using Prolong Antifade Gold.  Coverslips were imaged using a 60x oil 
immersion lens on a Nikon Eclipse Ti microscope with an Andor camera and NIS-
Elements imaging software. 
3.2.3 Live Cell Imaging 
For live cell imaging experiments, RPE-1 GFP-H2B/RFP-NLS and U2OS GFP-
H2B/RFP-NLS cells were plated on glass bottom imaging dishes from MatTek.  All live 
imaging experiments were performed using a Nikon Eclipse Ti microscope with Nikon 
perfect focus and an Andor camera.  This microscope has a chamber that is kept at 37°C 
and humidified 5% CO2.  Points were picked using the motorized stage and a Z-stack of 5 
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images every 2.5 µm was performed to track misaligned chromosomes as cells round up 
in mitosis.  Images were taken using a 20x lens every 5 min for 48–72 hr for RPE-1 and 
U2OS cells respectively using NIS Elements software. 
3.2.4 Generation of Micronuclei from Polar Chromosomes 
For experiments that produced micronuclei resulting from polar chromosomes, 
RPE-1 GFP-H2B/RFP-NLS cells were plated at 60,000 cells/well and U2OS GFP-
H2B/RFP-NLS cells were plated at 30,000 cells/well, each in 500 µl of media in the 
bottom of the well so that they plated evenly.  After giving the cells 2 hours to attach, 1.5 
ml of media was added to each well. The next day, the CENP-E inhibitor GSK-923295 
was added to the cells in fresh media at 1 µM for 2 hr to arrest cells in mitosis with polar 
chromosomes.  After points were picked for imaging and the video was initiated, the 
MPS1 inhibitor AZ-3146 was added to the dish in 1 ml media to a final concentration of 
2 µM so that the cells overcame the spindle assembly checkpoint and progressed into 
anaphase despite the presence of polar chromosomes.  All videos of cells with polar 
chromosomes lasted for 48 hr. 
3.2.5 Generation of Micronuclei from Lagging Chromosomes 
For experiments that produced micronuclei resulting from lagging chromosomes, 
RPE-1 GFP-H2B/RFP-NLS cells were plated at 20,000 cells/well and U2OS GFP-
H2B/RFP-NLS cells were plated at 10,000 cells/well, each in 500 µl of media in the 
bottom of the well so that they plated evenly.  After giving the cells 2 hours to attach, 1.5 
ml of media was added to each well. The following day, cells were transfected with 
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MCAK siRNA; MCAK is a microtubule depolymerase that helps destabilize merotelic 
attachments.  Without MCAK, merotelic attachments persist longer, leading to an 
increased propensity to develop micronuclei from lagging chromosomes.  Videos with 
RPE-1 GFP-H2B/RFP-NLS had a 48 hr duration; videos with U2OS GFP-H2B/RFP-
NLS cells had a 72 hr duration. Imaging was initiated 24 hr after transfection. 
3.3 Results 
3.3.1 Aurora B Phosphorylation Gradient 
It has been shown that rupture of the nuclear envelope of micronuclei during S 
phase can lead to extensive amounts of DNA damage and promote chromothripsis.  
However, how these micronuclei that undergo nuclear envelope rupture were formed was 
not tracked.  We hypothesize that micronuclei that develop as a result of lagging 
chromosomes are inherently different than micronuclei that develop as a result of polar 
chromosomes.  This hypothesis is based on the fact that cells with lagging chromosomes 
have been shown to have a delay in nuclear envelope formation. This delay in nuclear 
envelope formation is a result of the presence of Aurora B at the spindle midzone keeping 
histones phosphorylated.  Polar chromosomes, being stuck at the spindle pole, never enter 
an area of high Aurora B activity while lagging chromosomes have an extended residence 
in an area of high Aurora B activity.  We hypothesized that micronuclei resulting from 
polar chromosomes would have a nuclear envelope that is more stable than micronuclei 
that are a result of lagging chromosomes. 
To investigate this hypothesis, we first sought to verify that polar chromosomes 
were outside of an area of Aurora B activity while lagging chromosomes had an extended 
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stay in an area of high Aurora B activity.  We induced polar chromosomes in RPE-1 cells 
using a CENP-E inhibitor for 2 hr and then treating them with MPS1 inhibitor to bypass 
the spindle assembly checkpoint, as in the live cell imaging experiments. We fixed the 
cells 35 minutes after addition of the MPS1 inhibitor and stained them for phosphorylated 
histone H-3, labeling the DNA with Hoechst.  We also stained the cells for tubulin to 
verify that they were in anaphase.  Our data indicate that lagging chromosomes are 
positive for p-H3 while chromosomes away from the spindle midzone, including polar 
chromosomes were negative for p-H3; representative images can be seen in Figure 3.5. 
3.3.2 Stability of Nuclear Envelope in Micronuclei 
After verification of the Aurora B phosphorylation gradient, we performed 
experiments to determine the stability of the nuclear envelope in micronuclei formed 
from both polar and lagging chromosomes.  We used normal RPE-1 cells stably 
expressing histones tagged with green fluorescent protein (GFP-H2B) and nuclear 
localization signal tagged with red fluorescent protein (RFP-NLS). We induced 
micronuclei formation from polar chromosomes using a CENP-E inhibitor.  Since cells 
with polar chromosomes induce cell cycle arrest in mitosis, we used an MPS1 inhibitor to 
overcome activation of the spindle assembly checkpoint and allow the cells to progress 
through anaphase.  To induce micronuclei from lagging chromosomes, we transfected 
cells with MCAK siRNA, which stabilizes merotelic attachments.   We tracked the cells 
using live cell imaging for 24 hr after micronuclei formation to evaluate nuclear envelope 
rupture.  When the nuclear envelope of the micronuclei ruptures, the RFP-NLS signal is 
lost and the micronuclei go from having both green and red fluorescence to only having 
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green fluorescence.  As RPE-1 cells are normal and have intact tumor suppressor 
pathways, RPE-1 cells with micronuclei will not enter mitosis.  Micronuclei were defined 
as being stable if they were able to be tracked for at least 12 hours without rupture.  The 
data in Figure 3.6 show that the nuclear envelopes of micronuclei formed from polar 
chromosomes are significantly more stable than those formed from lagging chromosomes 
(p = 0.0070, Fisher Exact Test) in RPE-1 cells. 
To verify these findings in a transformed cell line we used U2OS cells, a near-
tetraploid osteosarcoma cell line.  Cancer cells have less stable nuclear envelopes than 
normal cells, even in the primary nucleus.  Furthermore, U2OS cells have some level of 
chromosome instability at baseline because of their near-tetraploid state.  We induced 
micronuclei formation from polar and lagging chromosomes in U2OS cells exactly as in 
RPE-1 cells.  Since U2OS cells take longer to go through the cell cycle than RPE-1 cells 
and some U2OS cells will enter mitosis even with micronuclei, we tracked these cells for 
48 hours after micronuclei formation or until they entered mitosis.  The data in Figure 3.7 
show that the nuclear envelopes of micronuclei formed from polar chromosomes are 
significantly more stable than those formed from lagging chromosomes in U2OS cells (p 
= 0.0448, Fisher Exact Test). The fold difference in nuclear envelope stability was 
smaller for U2OS cells than it was for RPE-1 cells, which is likely a result of the 
instability of cancer cell nuclear envelopes in general.  Representative images taken from 
live cell imaging videos show a stable micronucleus formed from a polar chromosome 
and an unstable micronucleus formed from a lagging chromosome in Figure 3.8 and 3.9 
respectively. 
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3.4 Conclusion 
These data demonstrate that micronuclei formed from polar chromosomes are 
inherently different than micronuclei formed from lagging chromosomes.  The nuclear 
envelopes of micronuclei formed from polar chromosomes are significantly more stable 
than those of micronuclei formed from lagging chromosomes.  This is presumably due to 
the activity of Aurora B, which is localized at the spindle midzone when cells transition 
from metaphase to anaphase.  Lagging chromosomes remain in an area of high Aurora B 
activity and their histones therefore stay phosphorylated in anaphase, delaying nuclear 
envelope reassembly.  Polar chromosomes, on the other hand, are in an area of low 
Aurora B activity at the onset of anaphase, so their histones are dephosphorylated 
normally, and they do not have a delay in nuclear envelope reassembly.  Consequently, 
the nuclear envelopes of micronuclei formed from polar chromosomes are significantly 
more stable than those of lagging chromosomes.  Since ruptured micronuclei have been 
shown to possess extensive amounts of DNA damage due to the catastrophic event 
known as chromothripsis, these results indicate that micronuclei that are formed from an 
abnormal mitosis with polar chromosomes are less likely to undergo chromothripsis than 
those that are formed as a result of lagging chromosomes.  Furthermore, cells with stable 
micronuclei formed from polar chromosomes may be less likely to promote 
tumorigenesis since they would not have the extensive amounts of DNA damage seen in 
ruptured micronuclei. 
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Figure 3.1: Aurora B destabilizes incorrect kinetochore-microtubule attachments 
Aurora B phosphorylates the NDC80 complex component KNL1 to destabilize incorrect 
kinetochore-microtubule attachments.  When microtubules from both spindle poles are 
properly attached to kinetochores, the tension pulls the kinetochore components away 
from Aurora B so they cannot be phosphorylated, and the kinetochore-microtubule 
interactions are stabilized. (Wurzenberger & Gerlich, 2011) 
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Figure 3.2: Aurora B activity in mitosis 
(A) Aurora B activity as measured by a FRET sensor in metaphase, early anaphase, and 
late anaphase.  A low emission ratio (blue-purple) indicates a high level of Aurora B 
activity while a high emission ratio indicates a low level of Aurora B activity. (B) Aurora 
B phosphorylation gradient, visualized by looking at phosphorylation of histone H3.  
(Fuller et al., 2008) 
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Figure 3.3: Polar chromosomes 
Polar chromosomes, induced by treatment with a CENP-E inhibitor.  Chromosomes are 
labeled with GFP-H2B. 
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Figure 3.4: CENP-E mediated chromosome congression 
Chromosome congression is mediated by the kinesin CENP-E.  Chromosomes (blue) are 
“walked” along existing bundles of microtubules (green) through action of the kinesin 
CENP-E, which is bound to kinetochores (red).  Adapted from Kapoor et al. (2006). 
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Figure 3.5: Aurora B activity in RPE-1 cells 
Representative images of RPE-1 cells imaged to validate Aurora B activity.  
Chromosomes were stained using Hoechst (white); Microtubules were stained using 
tubulin (green); Aurora B activity is indicated by staining for histone H3 phosphorylation 
(p-H3; red).  Lagging chromosomes were positive for p-H3 while polar chromosomes 
were negative for p-H3. 
  
	86	
 
 
 
 
Figure 3.6: Nuclear envelope stability in RPE-1 micronuclei. 
Micronuclei formed from polar chromosomes are inherently more stable than micronuclei 
formed from lagging chromosomes in RPE-1 cells. 
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Figure 3.7: Nuclear envelope stability in U2OS micronuclei. 
Micronuclei formed from polar chromosomes are inherently more stable than micronuclei 
formed from lagging chromosomes in U2OS cells. 
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Figure 3.8: Polar micronuclei stability in a RPE-1 cell 
Representative images from live cell imaging of the stages of micronuclei formation and 
evaluation of nuclear envelope rupture in CENP-E treated cells with a stable nuclear 
envelope.  Cells treated with CENP-E inhibitor induces chromosomes (GFP-H2B 
labeled) that are localized to the spindle poles in metaphase and are separated enough 
from the main chromosome mass during anaphase that they are enclosed in their own 
nuclear envelope as can be seen in interphase. If the nuclear envelope of the micronuclei 
remains intact, RFP-NLS signal remains in the micronuclei at the end fate. 
 
	89 
		
		
Figure 3.9: Lagging micronuclei stability in a U2OS cell 
Representative images from live cell imaging of the stages of micronuclei formation and evaluation of nuclear envelope 
rupture in MCAK siRNA transfected cells with an unstable nuclear envelope.  Cells transfected with MCAK siRNA appear 
normal in metaphase but induce lagging chromosomes in anaphase that are delayed enough in segregating that they form a 
micronuclei as can be seen in interphase.  When the nuclear envelope ruptures the RFP-NLS signal is lost from the 
micronuclei, and the micronuclei appears bright green at the end fate.   	
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4   DEFECTS IN KINETOCHORE ASSEMBLY IN MICRONUCLEI 
4.1 Introduction 
Micronuclei are formed when a cell goes through mitosis abnormally, entering 
telophase with one or a few chromosomes separated far enough from the main 
chromosome mass such that two nuclear envelopes form, one around the primary nucleus 
and the other around a micronucleus.  Micronuclei have a number of defects associated 
with them, including being prone to rupture and having impaired DNA damage repair, as 
discussed in Chapter 3 of this dissertation.  Additionally, there are a number of studies 
indicating that micronuclei have deficiencies in chromatin replication, DNA 
transcription, and DNA replication, although there is some conflicting evidence (Terradas 
et al., 2012).  Chromatin replication in micronuclei was shown to be defective in the 
majority of micronuclei in a couple of studies, but only in 1% of micronuclei in another 
study (Kramer, Schaich-Walch, & Nusse, 1990; Obe, Beek, & Vaidya, 1975; Terradas et 
al., 2012).  Terradas et al. (2012) showed that in some cells with multiple micronuclei, 
one micronucleus has chromatin that is replicating in S phase, while another 
micronucleus does not have evidence of chromatin replication, indicating that the ability 
of chromatin to replicate likely depends on the contents of the micronuclei. 
DNA transcription has also been shown to be impaired in micronuclei.  DNA 
transcription relies on proteins, such as transcription factors and RNA polymerase, which 
are transported from the cytoplasm into the nucleus through nuclear pore complexes 
(NPCs). Consequently, inefficient DNA transcription in micronuclei could be a result of 
an abnormal nuclear envelope, either completely lacking or with a reduced number of 
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NPCs (Terradas et al., 2012).  It has been reported that micronuclei have a heterogeneous 
distribution of NPCs as well as lamina gaps in the nuclear envelope (Geraud et al., 1989).  
In cells with micronuclei formed from broken anaphase bridges, less than 15% of 
micronuclei had evidence of DNA transcription; micronuclei that do show evidence of 
DNA transcription were also positive for lamin-B, indicating that the nuclear envelope 
was less disrupted (Hoffelder et al., 2004; Utani, Kawamoto, & Shimizu, 2007).  This 
suggests that nuclear envelope integrity, and thus nuclear import is important for DNA 
transcription. 
DNA replication, the copying of the genome, is similarly impaired in micronuclei.  
Crasta et al. (2012) found that in S phase, DNA replication is significantly diminished in 
micronuclei as compared to primary nuclei.  Correspondingly, factors known to be 
required for DNA replication are markedly reduced in micronuclei (Crasta et al., 2012).  
Furthermore, about a third of micronuclei show evidence of DNA replication while the 
cell is in G2.  No primary nuclei showed evidence of undergoing DNA replication in G2, 
demonstrating that DNA replication is asynchronous as well as inefficient in many cells 
with micronuclei (Crasta et al., 2012).  Clearly, defects in nuclear import can have 
important consequences for the function micronuclei, as some DNA replication factors 
also require nuclear import from the cytosol.   
Interestingly, kinetochores – the proteinaceous structures that are responsible for 
connecting spindle microtubules to the chromosome – are partially assembled in late G2 
in preparation for mitosis.  The kinetochore is an extremely complex structure, composed 
of over a hundred individual proteins organized into distinct sections, namely the inner 
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kinetochore and the outer kinetochore, which can be seen in Figure 4.1 (Cheeseman & 
Desai, 2008).  The inner kinetochore consists of a number of “centromere proteins,” so 
named because they form the interface between the kinetochore and the centromere on 
the chromosome.  The outer kinetochore consists of a number of complexes – such as the 
KMN network, made up of the KNL1, MIS12, and NDC80 complexes.  These complexes 
are important for assembling the kinetochore in the proper location as well as promoting 
and regulating proper kinetochore-microtubule attachments (Cheeseman et al., 2006; 
Cheeseman & Desai, 2008; Lampson & Cheeseman, 2011).  The NDC80 complex 
(known as Hec1 in eukaryotes) is noteworthy as it is the component of the kinetochore, 
which is crucial for proper kinetochore-microtubule attachments (DeLuca et al., 2005; 
DeLuca et al., 2006).  As it is so complex, assembly of the kinetochore requires nuclear 
import of many kinetochore proteins in G2.  We hypothesized that abnormal nuclear 
import may impair normal kinetochore assembly on the chromosomes in the micronuclei, 
which could hinder microtubule attachment and normal segregation in the following 
anaphase.  This, in turn could cause aneuploidy, the formation of more micronuclei, 
chromosome and genome instability. 
4.2 Methods 
4.2.1 Cell Culture 
Retinal pigment epithelial cells lacking the p53 pathway (RPE-1 p53-/-) were 
grown and maintained at 40–80% confluency in phenol red free DMEM:F12 media 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.  The 
osteosarcoma cell line, U2OS, was also grown and maintained at 40–80% confluency in 
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phenol red free DMEM:F12 media supplemented with 10% FBS and 1% 
penicillin/streptomycin.  The squamous cell carcinoma cell line, SCC-114 was grown and 
maintained at 40–80% confluency in DMEM:F12 media supplemented with 10% FBS 
and 1% penicillin/streptomycin. All cells were kept in an incubator at 37°C supplemented 
with 5% CO2. 
4.2.2 Immunofluorescence 
Cells on coverslips were fixed and stained as follows.  Each coverslip was washed 
with PBS for 1 minute and fixed using 4% paraformaldehyde in PBS for 15 minutes.  
Cells were then extracted for 5 minutes in 0.5% Triton in PBS and blocked in TBS-5% 
BSA for 30 minutes.  Cells were incubated in primary antibody for 1 hr, washed in PBS 
for 1 min then TBS-5% BSA for 5 min, incubated in fluorescently-labeled secondary 
antibody for 30 min, washed in PBS for 1 min then TBS-5% BSA for 5 min.  Primary 
antibodies were diluted in TBS-5% BSA while secondary antibodies were diluted in 
TBS-5% BSA + Hoechst to stain the DNA.  Finally, coverslips were mounted to slides 
using Prolong Antifade Gold.  Coverslips were imaged using a 60x oil immersion lens on 
a Nikon Eclipse Ti confocal microscope with a Nikon C2 camera, 405, 488, 561, and 640 
nm lasers and NIS-Elements imaging software. 
4.3 Results 
4.3.1 Efficiency of Kinetochore Assembly in Micronuclei 
It has previously been shown that micronuclei are inefficient at replicating DNA, 
even when the nuclear envelope is intact.  Although DNA replication and the assembly of 
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a proteinaceous structure such as the kinetochore seem to be very different processes, 
they are similar in that they are both dependent on nuclear import of proteins found in the 
cytosol.  The lack of a functional kinetochore would be deleterious for a cell entering 
mitosis because without a functional kinetochore, a chromosome is not able to attach to 
the mitotic spindle via kinetochore-microtubule interactions.  Furthermore, without a 
kinetochore, proteins that activate the spindle assembly checkpoint will not be able to 
recognize that there are chromosomes that are not properly attached. Consequently, the 
spindle assembly checkpoint will be satisfied even though the chromosome(s) from the 
micronuclei are unattached.  This will lead to a cell entering anaphase without control 
over where the micronuclear chromosomes are pulled, leading to the potential 
missegregation of chromosomes and chromosome instability. 
To identify kinetochores built in micronuclei, we fixed cells and stained them 
with CENP-A to mark centromeres – the segment of the chromosome that connects sister 
chromatids – and DSN1 to mark kinetochores, the proteinaceous structure that assembles 
on the centromere to facilitate proper chromosome segregation.  Kinetochores are 
assembled in late G2 phase, so cells were only counted if chromosomes had already 
started to compact or if all centromeres in the main nucleus were co-localized with DSN1 
staining.  We scored micronuclei in these cells as having a kinetochore if DSN1 staining 
co-localized with CENP-A staining in the micronuclei and as lacking a kinetochore if 
there was no DSN1 foci in the micronuclei, despite CENP-A foci indicating presence of a 
centromere. Experiments were performed in RPE-1 p53-/- cells – a diploid, non-
tumorigenic cell line lacking the p53 pathway so the cells proceed through the cell cycle 
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– as well as U2OS and SCC-114 cell lines, an osteosarcoma and oral squamous cell 
carcinoma cell line, respectively.  Every centromere should co-localize with a 
kinetochore if kinetochores are being assembled efficiently.  The data, in Table 4-1, show 
that all three cell lines investigated fail to efficiently assemble kinetochores on 
chromosomes in micronuclei.  RPE-1 p53-/- and U2OS cells have the most severe defect, 
with more than 80% of cells with micronuclei failing to assemble kinetochores on the 
centromeres of chromosomes in those micronuclei.  SCC-114 cells were more efficient at 
assembling kinetochores than RPE-1 p53-/- and U2OS cells, but still failed to assemble 
kinetochores efficiently in over 40% of micronuclei.  Representative images of these cells 
and micronuclei can be seen in Figures 4.2 (RPE-1 p53-/-), 4.3 (U2OS), and 4.4 (SCC-
114). 
4.4 Conclusion 
Micronuclei are known to be deficient as compared to primary nuclei in 
chromatin replication, DNA transcription, and DNA replication.  Here, we show that 
micronuclei also have a deficiency in kinetochore assembly, with anywhere from 40–
85% of micronuclei failing to build kinetochores before entry to mitosis in a variety of 
cell types.  This lack of kinetochores is problematic as chromosomes that do not have 
kinetochores cannot attach to the mitotic spindle, as microtubules attach the spindle pole 
to the kinetochore in order to facilitate proper chromosome segregation.  Consequently, a 
lack of kinetochores can lead to aneuploidy and chromosome instability, both of which 
are tumorigenic.   
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Figure 4.1: Kinetochore architecture in eukaryotes. 
The kinetochore is an extremely complex proteinaceous structure responsible for proper 
segregation of chromosomes by connecting the chromosome to the mitotic spindle via 
kinetochore-microtubules.  Kinetochore-microtubule attachments are mediated by the 
Hec1 complex. (Chan, Liu, & Yen, 2005) 
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Cell Line CENP-A+; DSN1- 
RPE-1 p53-/- 83.9% (n=62) 
U2OS 80.3% (n=61) 
SCC-114 44.6% (n=74) 
 
Table 4.1: Kinetochore assembly in micronuclei 
The percent of micronuclei that do not efficiently assemble kinetochores.  Inefficient 
kinetochore assembly is defined as being positive for the centromere marker, CENP-A 
but negative for the kinetochore marker, DSN1. 
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Figure 4.2:  Kinetochore assembly in micronuclei in RPE-1 p53-/- cells.  
One plane of the cell is shown, though all planes were evaluated for CENP-A/DSN1 co-
localization.  Centromeres stained with CENP-A (green) and kinetochores stained with 
DSN1 (red). 
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Figure 4.3: Kinetochore assembly in micronuclei in U2OS cells.  
One plane of the cell is shown, though all planes were evaluated for CENP-A/DSN1 co-
localization.  Centromeres stained with CENP-A (green) and kinetochores stained with 
DSN1 (red).  
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Figure 4.4:  Kinetochore assembly in micronuclei in SCC-114 cells.   
Max projection of the cell is shown.  Centromeres stained with CENP-A (red) and 
kinetochores stained with DSN1 (green). 
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5   DISCUSSION AND FUTURE DIRECTIONS 
As a whole, this dissertation identifies multiple mechanisms that facilitate 
tumorigenesis from tetraploid intermediates.  First, we identified miRNAs whose 
overexpression enables the proliferation of tetraploid cells and subsequently 
mechanistically defined how each miRNA does this.  We determined that miRNAs can 
enable tetraploid cell proliferation by the following mechanisms: inhibition of the p53 
tumor suppressor pathway; hyperactivation of growth factor signaling; and inactivation of 
the Hippo tumor suppressor pathway.  Second, we evaluated the stability of the nuclear 
envelopes of micronuclei formed from lagging and polar chromosomes as nuclear 
envelope rupture leads to massive amounts of DNA damage and chromothripsis.  Finally, 
we evaluated the efficiency of kinetochore assembly in micronuclei, as micronuclei are 
known to be defective at nuclear import of proteins, many of which are required for the 
assembly of the kinetochore.   
5.1 miRNAs Enable Tetraploid Cell Proliferation through Multiple Mechanisms 
In our screen of all the known human miRNAs, we identified 26 that enable 
tetraploid cells to proliferate.  This is important because the proliferation of tetraploid cell 
has been shown to promote tumorigenesis (Fujiwara et al., 2005).  Furthermore, although 
miRNA expression is globally downregulated in cancer, there is a subset of miRNAs that 
has been identified as being upregulated in a number of solid tumors (Volinia et al., 
2006). This subset includes a few miRNAs that our screen also identified, such as miR-
191 and miR-24 which we determined upregulate growth factor signaling and inactivate 
the Hippo tumor suppressor pathway, respectively.   
		 102 
These miRNAs that enable tetraploid cell proliferation and are upregulated in 
cancer represent a potential therapeutic target in cancer therapy.  Patients could be treated 
with either anti-miRs or antagomiRs, both of which would target the upregulated miRNA 
itself.  Therapies involving miRNAs may be difficult to implement in the clinic, however. 
Since each miRNA has hundreds to thousands of targets, it would probably be difficult to 
give an antagomiR at an appropriate dose such that it does not have any off target effects 
and still efficiently targets the overexpressed miRNA in the tumor.  As with many 
chemotherapeutics, therapies that target miRNAs would likely be most effective if they 
could be targeted directly to the tumor. 
Furthermore, miR-24 might be able to be used as a biomarker to help inform 
selection of therapeutics in cancer patients.  If a person has an elevated level of miR-24, it 
can be assumed that the Hippo tumor suppressor pathway has been inactivated.  
Consequently, a Hippo pathway activator would be a useful drug to be used in 
combination with other chemotherapeutic agents.  Although Hippo pathway activators 
have not yet been developed, we expect that they will be in the relatively near future. 
To expand upon the data presented here, it would be beneficial if the relevant 
targets could be found for each of these miRNAs.  Since miRNAs have so many 
individual targets, it would be much more likely to be able to develop a beneficial 
therapeutic for the target of the miRNA rather than the miRNA itself.  Furthermore, it 
would be useful to identify the mechanism used by those miRNAs that we could not 
categorize by the assays we ran.  This could likely be accomplished by evaluating 
activation of the MAPK pathway by measuring ERK and p-ERK signaling, or by looking 
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at time courses of growth factor signaling – for both ERK and AKT. 
5.2 Nuclear Envelope Rupture of Micronuclei 
Our data demonstrate that micronuclei formed from polar chromosomes have 
nuclear envelopes that are significantly more stable than the nuclear envelopes of 
micronuclei formed from lagging chromosomes.  Consequently, micronuclei formed 
from lagging chromosomes are significantly more likely to acquire DNA damage and 
undergo chromothripsis than those formed from polar chromosomes.  This is due to the 
fact that in addition to entry into S phase, chromothripsis requires nuclear envelope 
rupture.   
The fact that the nuclear envelopes of polar micronuclei are inherently more 
stable than those of lagging micronuclei is a novel and interesting finding.  However, we 
did not establish a mechanism for why this is the case.  We hypothesize that nuclear 
envelope stability is a result of the Aurora B gradient, as lagging chromosomes are in 
areas of high Aurora B activity while polar chromosomes are in areas of low Aurora B 
activity (Afonso et al., 2014; Fuller et al., 2008).  Furthermore, Aurora B has been shown 
to delay nuclear envelope reformation when there are lagging chromosomes (Karg et al., 
2015).  The most likely explanation for this difference, is that lagging chromosomes 
possess a decreased number of lamins or a discontinuity in the nuclear lamina.  In order 
to investigate this hypothesis, we could fix cells on coverslips and stain them for lamins.  
By comparing the fluorescence intensity of micronuclei to the fluorescence intensity of 
the primary nuclei, the integrity of the nuclear lamina could be analyzed.  Staining for 
lamins would also allow for the analysis of gaps in the lamina using high resolution 
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microscopy. 
The discovery that micronuclei generated from CENP-E inhibition are 
significantly more stable than micronuclei generated from lagging chromosomes also 
may inform the results of previous studies of aneuploidy.  In particular, Weaver et al. 
(2007) used a CENP-E hemizygous (CENP-E+/-) mouse model in order to evaluate how 
aneuploidy initiates tumorigenesis.  They found that CENP-E+/- mice did develop tumors 
more often than mice that had wild type CENP-E.  However, tumors did not develop in 
the majority of mice, with lymphomas in the spleen occurring in 10% of CENP-E+/- mice 
and tumors in the lung also occurring in 10% of CENP-E+/- mice (Weaver et al., 2007).  
We now know that this model likely creates less DNA damage than a model that 
generates aneuploidy from lagging chromosomes.  Accordingly, aneuploidy generated 
from alternate mechanisms may in fact initiate tumorigenesis more frequently than 
Weaver and colleagues found in their CENP-E+/- mouse model. 
5.3 Kinetochore Assembly is Inefficient in Micronuclei 
We showed here that micronuclei are extremely inefficient at assembling 
kinetochores and this inefficiency is consistent across multiple cell lines.  This finding is 
likely indicative of a decreased number of nuclear pore complexes (NPCs) as kinetochore 
assembly is dependent on the nuclear import of many proteins.  This could be confirmed 
by staining cells for nucleoporins, the proteins that form NPCs, and comparing the 
density of NPCs in micronuclei the density of NPCs in primary nuclei. 
The failure of micronuclei to assembly kinetochores can lead to chromosome 
instability due to the lack of proper chromosome alignment to the mitotic spindle.  
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Chromosome instability generally correlates with poor prognosis in cancer.  Micronuclei 
themselves are a result of errors in chromosome segregation, often as a result of 
proliferating tetraploid cells.  Consequently, the proliferation of tetraploid cells not only 
leads to cancer, but can also lead to micronuclei, chromothripsis, chromosome instability, 
and poor prognosis in cancer patients.  By identifying miRNAs that enable tetraploid cell 
proliferation and characterizing abnormalities in micronuclei, we have contributed to the 
growing body of knowledge of tetraploid cells which will hopefully eventually lead to 
therapies that can target tetraploid cells, or prevent them from proliferating initially since 
~20% of solid tumors are near-tetraploid and ~40% of cancers show evidence of being 
tetraploid at some point in the lineage of the tumor. 
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APPENDIX A – GENERATION AND PURIFICATION 
OF TETRAPLOID CELLS 
A.1 Introduction 
The vast majority of non-transformed human cells contain two copies of each 
chromosome and are termed diploid. In preparation for cell division, all chromosomes are 
replicated so that they may be evenly distributed to two daughter cells during mitosis. 
However, catastrophic failures in mitosis or cytokinesis can give rise to tetraploid cells, 
which have a doubled DNA content (4 copies of each chromosome). The generation of 
tetraploid cells through non-programmed mechanisms can have significant consequences, 
as spontaneously arising tetraploid cells are chromosomally unstable and have the 
capacity to promote tumorigenesis (Coward & Harding, 2014; Teresa Davoli & de Lange, 
2012; Duelli et al., 2007; Fujiwara et al., 2005; Neil J Ganem et al., 2009; N. J. Ganem et 
al., 2007; Lundberg et al., 2013; Sotillo et al., 2007; Storchova & Kuffer, 2008). It is now 
recognized that tetraploidization events are common in solid tumors, and correlate with 
poor prognosis (Dewhurst et al., 2014; Travis I Zack et al., 2013).  
Studying the biology of tetraploid cells can allow us to more fully understand how 
they promote tumor progression.  However, given their rarity in mixed populations of 
cells, it requires a rapid and efficient method to generate and purify them. Several 
methods currently exist to generate tetraploid cells. These include fusing diploid cells 
using polyethylene glycol (Wong & Stearns, 2005); inhibiting cytokinesis using cell 
permeable small molecules that prevent furrow ingression and cleavage (Andreassen et 
al., 2001; Carter, 1967; Fujiwara et al., 2005; N. J. Ganem et al., 2014; Wong & Stearns, 
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2005); and promoting mitotic slippage by using small molecules that prevent satisfaction 
of the spindle assembly checkpoint (Rieder & Maiato, 2004). Of these methods, 
inhibiting cytokinesis is the simplest and most effective way to generate tetraploid cells. 
In contrast to cell fusion experiments, which are highly inefficient and time consuming, 
or induction of mitotic slippage, which first requires a dramatically prolonged mitosis 
that produces extensive DNA damage and even cell death (N. J. Ganem & Pellman, 
2012; Orth, Loewer, Lahav, & Mitchison, 2012), inhibiting cytokinesis with small 
molecules can be achieved on large populations of cells without inducing mitotic 
abnormalities or DNA damage (N. J. Ganem et al., 2014; Krzywicka-Racka & Sluder, 
2011; Panopoulos et al., 2014). The most commonly used small molecules used to inhibit 
cytokinesis include blebbistatin, a myosin II inhibitor, and the cytochalasins, which 
disrupt actin polymerization (Carter, 1967; Straight et al., 2003). These compounds 
prevent cytokinetic furrow ingression and cell cleavage following anaphase, and thus lead 
to the formation of binucleated tetraploid cells.  
While several simple methods exist to generate tetraploid cells, purifying 
tetraploids from a predominantly diploid population of cells poses a significant technical 
challenge. One approach is size separation.  However, although tetraploid cells are larger 
than diploid cells, purification strategies based on cell size are inefficient (our 
unpublished data). Moreover, DNA content alone cannot distinguish diploid from 
tetraploid cells because diploid cells in G2/M phase of the cell cycle (which have 
replicated their chromosomes) have the same amount of DNA as tetraploid cells in G1 
phase of the cell cycle (both contain 4C DNA content). While tetraploid cells that 
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progress to G2/M and possess 8C DNA content can be readily distinguished from 
diploids, these cells are relatively rare because non-transformed tetraploids exhibit 
markedly reduced proliferation (Andreassen et al., 2001; N. J. Ganem et al., 2014). 
Here, we describe an approach to generate and purify tetraploid cells with high 
efficiency using the fluorescent, ubiquitin-based, cell cycle indicator (FUCCI) system 
(Sakaue-Sawano et al., 2008).  FUCCI consists of two fluorescently labeled proteins, 
truncated forms of hCdt1 (consisting of amino acids 30 to 120) and hGeminin (consisting 
of amino acids 1 to 110), whose expression alternates based on cell cycle progression.  
hCdt1 (fused to a red-fluorescent protein) is a DNA replication licensing factor that is 
present during G1 phase but is ubiquitinated by SCFSkp2 and degraded during S/G2/M 
phases. hGeminin (fused to a green-fluorescent protein) is a negative regulator of DNA 
licensing that is present during S/G2/M phases but is ubiquitinated by APCCdh1 and 
degraded at the end of mitosis and throughout G1 (see Note 1). Thus, FUCCI provides a 
simple, fluorescence readout of cell cycle position. This system provides a critical tool in 
overcoming the technical barrier of isolating tetraploids from diploids: FUCCI can be 
used to discriminate G1 tetraploids from G2/M, both of which possess 4C DNA content, 
because G1 tetraploids emit red fluorescence while G2/M diploids emit green 
fluorescence. 
A.2 Materials 
The following materials and equipment are used in this protocol: 
A.2.1 Cell Culture 
1. 10 cm2 polystyrene tissue culture plates. 
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2. 15 cm2 polystyrene tissue culture plates. 
3. Phenol red-free DMEM:F12 media supplemented with 10% fetal bovine serum 
(FBS), 100 IU/ml penicillin, and 100 µg/ml streptomycin (see Note 2). 
4. 0.25% Trypsin/EDTA. 
5. Sterile phosphate-buffered saline (PBS). 
6. Cell line of interest expressing the FUCCI reporter system (here we use the 
telomerase-immortalized human retinal pigment epithelial cell line RPE-1, from 
ATCC). It is also important to have unlabeled cells, cells expressing hCdt1-RFP 
alone, cells expressing hGem-GFP alone, and cells expressing the complete 
FUCCI system (both hCdt1-RFP and hGem-GFP, which we will refer to as RPE-
1 FUCCI)(see Note 3). 
7. Dihydrocytochalasin B (10 mM stock in DMSO).  
A.2.2 Fluorescence Activated Cell Sorting 
1. Hoechst 33342 (10 mg/ml in water). 
2. Polystyrene round bottom tubes with cell strainer caps (35 µM nylon mesh). 
3. Sterile 15 ml conical tubes. 
4. Sterile 50 ml conical tubes. 
5. 0.05% Trypsin/EDTA. 
6. Aluminum foil. 
A.2.3 Equipment 
1. Tissue culture incubator set at 37°C with 5% humidified CO2. 
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2. Tissue culture hood. 
3. Hemocytometer. 
4. High-speed centrifuge. 
5. Phase contrast microscope equipped with a 10X objective for cell counting. 
6. Standard epifluorescence microscope equipped with excitation and emission 
filters necessary to visualize fluorescence in three colors (e.g. 
DAPI/FITC/TRITC). 
7. FACS machine equipped with a UV laser (355 nM), a 488 nM laser, and a 561 
nM laser, and a 100 µM nozzle (see Note 4). 
A.3 Methods 
The following protocol describes the method used to generate and purify 
tetraploid RPE-1 cells using the FUCCI reporter system. In addition to growing RPE-1 
FUCCI cells (hCdt-mCherry and hGem-AzamiGreen), control RPE-1 cells expressing 
hCdt-mCherry alone, hGem-AzamiGreen alone, and unlabeled RPE-1 cells must also be 
carried (see Note 5). These will be used to calibrate the FACS machine. 
A.3.1 Cell Culture 
1. Use freshly thawed and early passage cells for all experiments. The cells should 
be maintained on 10 cm2 polystyrene tissue culture plates in phenol red-free 
DMEM:F12 media supplemented with 10% fetal bovine serum (FBS), 100 IU/ml 
penicillin, and 100  µg/ml streptomycin. Maintain the cells at 40–80% confluence. 
If the cells grow beyond 80% confluence, discard them and thaw fresh cells. 
Maintain cells for only 1–2 months before thawing fresh cells. 
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2. To set up a tetraploid purification experiment, expand RPE-1 FUCCI cells from 
10 cm2 tissue culture maintenance dishes into 15 cm2 dishes. Aspirate medium 
from each 10 cm2 tissue culture dish, wash with sterile PBS, and add 2.5 ml of 
0.25% Trypsin/EDTA. Incubate the cells in a tissue culture incubator at 37°C for 
~5 min or until most of the cells have detached. 
3. Collect the cells in 10 ml of complete medium to inactivate the trypsin, and then 
pellet the cells for 5 min at 280 x g in a high-speed centrifuge. 
4. Thoroughly resuspend the cells in 10 ml of complete medium. Count the cells 
with a hemocytometer. 
5. Plate 6 X 106 RPE-1 FUCCI cells per 15 cm2 dish. In general, one seeded 15 cm2 
dish will ultimately yield ~0.5–1 X 106 purified tetraploid cells following FACS. 
Scale up the number of dishes as needed. In addition, plate 2 X 106 unlabeled 
RPE-1 cells, RPE-1 cells expressing hCdt-mCherry, and RPE-1 cells expressing 
hGem-AzamiGreen into separate 10 cm2 dishes. These will be used to calibrate 
the FACS machine. 
A.3.2 Generating Tetraploid Cells 
Multiple approaches have been developed to generate tetraploid cells in vitro. These 
include inhibiting cytokinesis, promoting mitotic slippage, or fusing diploid cells. This 
protocol will focus on use of the cell permeable mycotoxin dihydrocytochalasin B 
(DCB), which disrupts actin polymerization and thus causes cytokinetic cleavage furrow 
regression, cytokinesis failure, and tetraploidy. This approach is beneficial for a number 
of reasons. First, this highly potent compound can be added to an entire population of 
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proliferating cells in order to generate a significant number of tetraploid cells. Second, 
this compound does not disrupt mitotic spindle assembly or the efficiency of 
chromosome segregation, and does not produce DNA damage. This is in contrast to drugs 
(e.g. Taxol, nocodazole), which induce tetraploidy by promoting prolonged mitotic arrest 
and mitotic slippage by preventing inactivation of the spindle assembly checkpoint. 
Finally, DCB is a reversible drug that can be washed from cells, thus enabling the 
inhibition of cytokinesis during only a single cell cycle. This is a major benefit over 
knocking out or knocking down the expression of genes essential for cytokinesis, which 
will induce repeated cytokinesis failures. To generate tetraploid cells: 
 
1. Dilute DCB to 4 µM (from a 10 mM stock) in complete 20 ml growth medium 
and mix thoroughly. Add the growth medium containing DCB to each of the 
RPE-1 FUCCI cells plated on 15 cm2 dishes the previous day (using a 10x 
objective on a phase contrast microscope, confirm that cells are 50–60% confluent 
at the time of DCB addition)(see Note 6). 
2. Incubate the cells in DCB for 16 hr in a 37°C tissue culture incubator (see Note 
7). It should be noted that since DCB disrupts the actin cytoskeleton, the 
morphology of the cells will be dramatically and visibly altered: the cells will 
have ruffled edges and will be less spread on the tissue culture dish. 
3. Aspirate the medium and gently rinse the cells with sterile PBS. 
4. Wash the cells 5 times (5 min each time) in pre-warmed growth medium. These 
washes are essential to completely remove residual DCB from the cells. The 
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DCB-treated cells should flatten out and assume a normal looking morphology 
immediately following the completion of these washes. At this point, ~40–60% of 
the cells should be visible as binucleated tetraploids under a phase contrast 
microscope. 
  
A.3.3 Purifying Tetraploid Cells by FACS 
1. Following the last wash, add complete growth medium containing 4 µg/ml 
Hoechst dye (to label the DNA) to the RPE-1 FUCCI cells. In addition, add 
growth medium containing 4 µg/ml Hoechst dye to the 10 cm2 dishes seeded with 
the unlabeled control RPE-1 cells, RPE-1 cells expressing hCdt-mCherry, and 
RPE-1 cells expressing hGem-AzamiGreen. Incubate all dishes at 37°C for 30 
min. 
2. Aspirate the medium from each tissue culture dish, wash with sterile PBS, and 
add 6 ml of 0.05% Trypsin/EDTA to each 15 cm2 dish (2.5 ml of Trypsin to the 
10 cm2 control dishes). Incubate the cells in the tissue culture incubator at 37°C 
for ~5 min or until the cells have detached (see Note 8). 
3. Collect the cells in 10 ml of complete medium to inactivate the trypsin, then pellet 
the cells for 5 min at 280 x g in a high-speed centrifuge. 
4. Resuspend the pelleted cells in complete medium containing 4 µg/ml Hoechst (for 
cells from one 10 or 15 cm2 dish, resuspend in 200 µl of medium; for each 
additional 15 cm2 dish, add 50 µl to the resuspension volume). Resuspend the 
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pellets thoroughly by slowly pipetting up and down with a p1000 pipette tip (~50 
times). 
5. To remove clumps, strain the resuspended cells through 35 µM nylon strainer 
caps into round bottom FACS tubes wrapped in aluminum foil. The cells are now 
ready to be FACS-sorted. 
6. Calibrate the FACS machine with the control cell lines. First, run the unlabeled 
diploid RPE-1 cells stained for Hoechst in order to calibrate the UV laser (355 
nm) and produce sharp 2C and 4C peaks (Figure A.1A). Second, run RPE-1 cells 
expressing hGem-AzamiGreen to define and gate AzamiGreen+ cells (use the 488 
nm laser). Third, run RPE-1 cells expressing hCdt1-mCherry alone to define and 
gate mCherry+ cells (use the 561 nm laser)(see Note 9). 
7. Once the FACS machine is properly calibrated, sort mCherry+/AzamiGreen-  2C 
cells (these represent G1 diploids) into one 15 ml conical tube containing 5 ml of 
complete growth medium (Figure A.1B). Sort mCherry+/AzamiGreen-  4C cells 
(these represent G1 tetraploids) into a separate 15 ml conical tube containing 5 ml 
of complete growth medium (Figure A.1B). Both collection tubes should be 
wrapped in aluminum foil. To ensure maximum viability, the FACS sorting 
should take no longer than 1 hr (see Note 10). 
8. Pellet the sorted cells for 5 min at 280 x g in a high-speed centrifuge, resuspend 
them in complete growth medium, and then count/plate into tissue culture dishes 
as needed. To assess purity, the sorted cells can be visualized by fluorescence 
microscopy once they have attached to the tissue culture dish (this takes ~1–3 hr). 
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Tetraploid cells, which are mCherry+ and AzamiGreen-, will appear as 
binucleated cells exhibiting red fluorescence (Figure A.1C, right panel). Because 
non-transformed tetraploid cells activate the Hippo tumor suppressor pathway and 
do not proliferate well, there will be few binucleated cells exhibiting green 
fluorescence (indicative of S-phase entry). By contrast, diploid cells will be 
mononucleated and exhibit both red and green fluorescence, as these cells resume 
proliferation immediately following the sorting procedure (Figure A.1C, left 
panel). In general, the tetraploid population should be 85–95% pure.  
 
A.4 Notes 
1. The FUCCI system was developed by Dr. Atushi Miyawaki’s group at the 
laboratory for Cell Function and Dynamics at the Riken Brain Science Institute 
and is commercially available through many sources. Information about the 
constructs can be found at: http://cfds.brain.riken.jp/Fucci.html.  
2. The use of phenol-red free medium is not required, however, the absence of 
phenol red decreases background fluorescence and improves the efficiency of 
FACS sorting. 
3. Both lentiviral and retroviral vectors expressing components of the FUCCI system 
can be used to generate stable cell lines. Live-cell imaging should be used to 
confirm that the reporter constructs are cycling properly. Both hCdt1-mCherry 
and hGem-AzamiGreen should localize exclusively to the nucleus (except during 
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mitosis, when the nuclear membrane breaks down and hGem-AzamiGreen 
becomes diffuse throughout the cytoplasm). 
4. Because of the increased size of tetraploid cells, the 100 µM nozzle is less likely 
to clog than smaller nozzle sizes. 
5. The original FUCCI reporters consisted of hCdt1(30/120) fused to the fluorescent 
protein Kusabira orange-2, and hGem(1/110) fused to the fluorescent protein 
AzamiGreen. Kusabira orange-2 maximally absorbs light at 551 nm and emits 
light at 565 nm, while AzamiGreen maximally absorbs light at 492 nM and emits 
light at 505 nM. A second generation version of FUCCI consists of 
hCdt1(30/120) fused to mCherry (absorbs light at 587 nm and emits at 610 nm), 
and hGem(1/110) fused to mVenus (absorbs light at 515 nm and emits at 528 
nm). We found that pairing hCdt1(30/120)-mCherry with hGem(1/110)-
AzamiGreen was most ideal, as the mCherry and AzamiGreen emission spectra 
were the most spatially separated and thus limited any bleed-through 
fluorescence. 
6. The confluence of cells is critically important at the time of DCB addition. 
Because DCB disrupts the actin cytoskeleton, sparsely plated cells are more likely 
to become detached from the tissue culture dish. Conversely, if cells are too dense 
at the time of DCB addition, cellular proliferation will be slowed and cells may 
reach overconfluence by 16 hr. 
7. Disruption of the actin cytoskeleton by DCB will prevent cells in early G1 phase 
from entering S-phase. Thus, only cells in late G1, S, G2, or M phases of the cell 
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cycle will proceed through mitosis and fail cytokinesis following DCB treatment. 
Incubation of cells with DCB for 16 hr is recommended because that is the 
approximate duration of the cell cycle in RPE-1 cells. Longer treatments in DCB 
will not produce additional tetraploid cells. 
8. We have observed that using 0.05% Trypsin instead of 0.25% Trypsin reduces the 
amount of cell clumping during FACS.  
9. Tetraploid cells, due to their increased size, tend to settle out of solution very 
quickly. Thus, it is important to periodically vortex the cellular resuspension 
during the sorting procedure. 
10. 1 hr is generally sufficient time to FACS sort cells from as many as 16 separate 15 
cm2 dishes. However, if more cells are required, it is recommended to use two 
FACS machines or stagger the experiments in order to limit the amount of time 
cells are kept in suspension. 		
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Figure A.1: FACS isolation of tetraploid cells.  
(A) A representative FACS profile of DNA content from RPE-1 FUCCI cells following 16 hr DCB treatment. The 2C peak 
contains G1 diploids while the 4C peak contains both G2/M diploids and G1 tetraploids. (B) Diploid and tetraploid cells within 
the 4C peak are distinguished by assessing mCherry (y-axis) and AzamiGreen (x-axis) fluorescence intensity. Tetraploid cells 
in G1 are mCherry+ and AzamiGreen- (top left quadrant), while diploid cells in G2/M are mCherry- and AzamiGreen+ (bottom 
right quadrant). (C) Sorted tetraploid cells generated by DCB treatment are binucleated (right panel) and can be easily 
distinguished from mononucleated diploid cells (left panel) by phase contrast and fluorescence microscopy. 
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